Y-box binding protein 1 inhibitors
Patent Information
- Application Number
- JP2023533819
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-10-17
- Filing Date
- 2021-12-03
- Publication Date
- 2024-11-29
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a need for small molecule inhibitors of Y-box binding protein 1 (YB-1) to address tumor progression and treatment resistance in various cancers, particularly ovarian cancer, as existing treatments are limited in efficacy and often lead to resistance.
Development of azopodophyllotoxin small molecule SU056, which potently inhibits YB-1 activity, sensitizes cancer cells to chemotherapy, and reduces progression of ovarian cancer by targeting YB-1, thereby inhibiting cell proliferation and apoptosis resistance.
SU056 effectively inhibits YB-1, enhancing chemotherapy sensitivity and reducing cancer progression without significant hepatotoxicity, offering a potential strategy to overcome treatment resistance in cancers like ovarian cancer.
Smart Images

Figure 2022120242000001 
Figure 2022120242000002 
Figure 2022120242000003
Abstract
Description
[Technical Field]
[0001] Field of Invention The present invention relates to novel compounds, pharmaceutical compositions, and their use as inhibitors of Y-box protein 1 (YB1 or YBX1) for treating conditions including gynecological cancers, breast cancer, bladder cancer, kidney cancer, head and neck cancer, neuronal cancer, prostate cancer, lymphoma, and leukemia. [Background technology]
[0002] Background of the Invention Y-box binding protein 1 (YB-1) is a multifunctional protein associated with tumor progression and the emergence of treatment resistance (TR). Here, we report the azopodophyllotoxin small molecule SU056, which potently inhibits tumor growth and progression via YB-1 inhibition. This first-in-class YB-1 inhibitor inhibits cell proliferation, apoptosis resistance, and arrests ovarian cancer (OC) cells at the G1 phase. Inhibitory treatment leads to enrichment of proteins associated with the apoptotic and RNA degradation pathways, while downregulating the splicesome pathway. In vivo, SU056 independently suppresses OC progression and, in synergy with paclitaxel, further reduces disease progression without observable hepatotoxicity. Furthermore, in vitro mechanistic studies showed delayed disease progression through inhibition of drug efflux and multidrug resistance 1 (MDR1), as well as significantly lower neurotoxicity compared to etoposide. These data suggest that YB-1 inhibition may be an effective strategy to reduce OC progression, counteract TR, and decrease patient mortality.
[0003] Y-box binding protein 1 (YB-1, YBX1) is a multifunctional cold-shock protein that binds to DNA and RNA. It regulates DNA and RNA-related cellular events, such as mRNA transcription, splicing, packaging, stability, and translation (Lyabin et al., 2014). mRNA stabilization is a critical event for the sustained expression of any gene, and YB-1 robustly stabilizes mRNA by inhibiting 5' end mRNA degradation (Evdokimova et al., 2001). It was first described by Didier et al. as a negative regulator of MHC class II molecules (Didier et al., 1988). The oncogenic role of YB-1 has been well-characterized in many cancers, and its amplified levels have been found in numerous cancer cases (Goodarzi et al., 2015). It increases the stability of short-lived mRNAs for several oncogenic proteins associated with disease progression and treatment resistance, such as c-myc (Laird-Offringa et al., 1990), c-fos (Blattner et al., 2000), cyclin B1 (Maity et al., 1995), HIF1α (Goodarzi et al., 2015), Snail (Evdokimova et al., 2009), and MDR1 (Bargou et al., 1997). Gene knockdown studies have demonstrated that inhibition of YB-1 significantly halts proliferation and induces apoptosis in many cancer models, demonstrating its essential role in disease progression (Evdokimova et al., 2009, El-Naggar et al., 2015). YB-1 is associated with the development of treatment resistance (TR) through its role in activating proliferation, promoting stem cell properties in cancer cells, responding to growth factors and cytokines, cellular stress responses, and promoting drug efflux via membrane P-glycoprotein and the ATP-dependent efflux pump ABCB1 (MDR1) (Bargou et al., 1997, Saupe et al., 2015, Mo et al., 2016).It is also involved in alternative splicing of the CD44 exon via binding to the A / C-rich region (Stickeler et al., 2001). The YB-1 gene is highly conserved, with only about 1% of cancer patients showing mutations, yet it is overexpressed in a wide range of cancers via the alternative gene regulatory network.
[0004] Ovarian cancer (OC) accounts for only 3% of all cancer cases in women, yet it causes a disproportionately high mortality rate (Dietl, 2014; Jayson et al., 2014; Agarwal and Kaye, 2003). Chemotherapy after surgical resection is the primary treatment strategy for OC patients. Platinum-based and taxol-based drugs, as well as combinations thereof, are the first-line treatment for the majority of OC patients (Seifter, 1997). The majority of women are diagnosed with OC at stage III+ and frequently experience triglycerides (TR) and disease recurrence. BRCA1 / 2 mutations, MYC amplification, and MDR1 (ABCB1 / P-gp) upregulation are the most common known causes of TR in OC (Zeng et al., 2018; Christie and Bowtell, 2017; Sun et al., 2015). Patient-based studies have shown that MYC amplification is associated with disease progression and triglyceride levels (TR) in many high-grade epithelial ovarian carcinoma (OC) lesions (Jung et al., 2017, Jung et al., 2018). Nuclear localization of YB-1 plays a crucial role in the regulation of MYC, MDR1, and CD44 (Kang et al., 2013, Sobocan et al., 2020). Analysis of high-grade ovarian serous carcinoma samples suggests that patients with higher YB-1 expression (median survival 48.5 months) had shorter survival times compared to those with lower YB-1 expression (median survival 65 months) (Kang et al., 2013). Following primary treatment with surgery and chemotherapy for occidental ovarian cancer (OC), maintenance therapy including long-term use of drugs such as paclitaxel and PARP inhibitors (olaparib, pazopanib, and niraparib) may be administered, but unfortunately, outcomes remain limited (Franzese et al., 2019). The literature over the past 30 years strongly suggests that YB-1 is a potential target for treating ovarian cancer and other cancers, including those that develop treatment resistance. Despite extensive research, little effort has been made to develop small molecule inhibitors that can directly inhibit YB-1.Y-box binding protein 1 (YB-1), encoded by the YBX1 gene, has attracted attention for its ability to modulate or regulate cellular signaling pathways and may be understood as a molecular marker for cancer progression and a target for cancer therapy.
[0005] In their review paper, YB-1: oncoprotein, prognostic marker and therapeutic target?, Biochem. J. (2013) 449, 11-13, Lasham et al. describe how "YB-1 can control multiple proliferation pathways, overcome cell cycle checkpoints, promote replicative immortality and genomic instability, regulate angiogenesis, play a role in invasion and metastasis, and promote inflammation." They further describe cell lines in which apoptosis was induced or cell proliferation was inhibited by YB-1 reduction, such as melanoma, fibrosarcoma, liver cancer, lung cancer, bladder cancer, multiple myeloma, pediatric glioblastoma, breast cancer (ER-negative), breast cancer (ER-positive), prostate cancer, and colon cancer.
[0006] Sobocan et al. (Can 2020, 12, 205) reported that dual targeting of Y-box protein 1 (YB-1) and mTOR improves inhibition of oncogenic activity in gynecological cancers, such as ovarian cancer, endometrial cancer, fallopian tube cancer, and cervical cancer.
[0007] The paper, "Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer," Kuwano et al., Cancer Science, 2019, 110: 1536-1543, describes the function of YBX2 in promoting transcriptional activation of the ABCB1 transporter gene, which has been associated with the transcriptional mechanism by which multidrug resistance to tumors is acquired during chemotherapy treatment in human malignancies, such as breast cancer, lung cancer, ovarian cancer, prostate cancer, colorectal cancer, and gastric cancer.
[0008] The relationship between increased YBX1 expression and melanoma is described in the paper, *The increased expression of Y box-binding protein 1 in melanoma stimulates proliferation and tumor invasion, antagonizes apoptosis and enhances chemoresistance*, Schittek et al., Int.J.Cancer:120, 2110-2118 (2007). YB1 overexpression has also been associated with radioresistance in colorectal cancer cells, as described by Kim et al., Mol. Cancer Ther., 30 Oct 2019, 19(2), 479-89.
[0009] WO 2019 / 178091 A1 (Malholtra et al., The Board of Trustees of the Leland Stanford Junior University) teaches novel N-hydroxyethyl didehydroazapodophyllotoxins as GBP1 inhibitors and how to use them in overcoming cancer treatment resistance. Included in the disclosure are specific compounds, 9-(3-fluorophenyl)-5-(2-hydroxyethyl)-6,9-dihydro-[1,3]dioxolo[4,5-g]fl[3,4-b]quinoline-8(5H)-one(SU056); 5-(2-hydroxyethyl)-9-(3-(trifluoromethyl)phenyl These are nolin-8(5H)-one; 3-(5-(2-hydroxyethyl)-8-oxo-5,6,8,9-tetrahydro-[1,3]dioxolo[4,5-g]fl[3,4-b]quinoline-9-yl)benzonitrile; and 5-(2-hydroxyethyl)-9-(pyridine-4-yl)-6,9-dihydro-[1,3]dioxolo[4,5-g]fl[3,4-b]quinoline-8(5H)-one.
[0010] There is still a need for small molecule inhibitors of YB-1 for pharmaceutical use.
Summary of the Invention
[0011] Biological equivalence is considered an important tool for rational drug design because medicinal chemists can quickly manipulate lead structures to optimize potency and selectivity, absorption, distribution, metabolism, and excretion (ADME) properties. Here, the inventors used a structure-based approach to optimize the anti-OC effect of a lead compound using bioisosteric substitution and then performed target identification via cellular thermal shift assay (CETSA) (Savitski et al., 2014). Through in vitro and in vivo studies, the inventors showed that the azopodophyllotoxin (AzP) small molecule SU056 potently inhibits YB-1 while sensitizing to chemotherapy-mediated cytotoxicity and reducing the progression of OC.
[0012] One aspect provides a compound of formula (I): TIFF2023552368000002.tif40128 or a pharmaceutically acceptable salt, pharmaceutically acceptable cocrystal, pharmaceutically acceptable ester, pharmaceutically acceptable solvate, hydrate, isomer (including optical isomers, racemic compounds, or other mixtures thereof), tautomer, isotope, polymorph, and pharmaceutically acceptable prodrug thereof, where X is TIFF2023552368000003.tif36159 selected from the group of; R1, R2, R3, R4, and R5 are each independently selected from the group of H, F, C1-C4 fluoroalkyl, SF5, Cl, Br, I, OH, C1-C4 alkyl, C1-C4 alkoxy, CN, NO2, and OH; n is an integer independently selected in each case from the group of 1, 2, 3, 4, 5, and 6; R6 is H, C1-C6 alkyl, C3-C6 cycloalkyl, -(CH2) n-C3-C6 cycloalkyl, 3- to 6-membered heterocyclic ring, -(CH2) n -3- to 6-membered heterocyclic ring, phenyl, and -(CH2) n -selected from the group of phenyl; the C1-C6 alkyl group is substituted with 0, 1, 2, 3, or 4 substituents selected from F, Cl, Br, I, OH, CN, NO2, and OH; C3-C6 cycloalkyl, -(CH2) n -C3-C6 cycloalkyl, 3- to 6-membered heterocyclic ring, -(CH2) n -3- to 6-membered heterocyclic ring, phenyl, and -(CH2) n -the phenyl group is substituted with 0, 1, 2, 3, or 4 substituents selected from the group of C1-C3 alkyl, C1-C3 alkoxy, F, Cl, Br, I, OH, CN, NO2, and OH; however, at least one of R1, R2, R3, R4, and R5 is selected from the group of F, C1-C4 fluoroalkyl, and SF5; however, when X is TIFF2023552368000004.tif36128 and R2 is F or CF3, at least one of R1, R3, R4, and R5 is not H.
Brief Description of the Drawings
[0013] [Figure 1] Figure 1A illustrates the conversion of SU093 to SU056. Figure 1B is a table showing the IC50 values of SU093 and SU056 against various ovarian cancer cells. Figure 1C shows photographs of colony formation from each well. Figure 1D is a graph showing the number of colonies formed after treatment with SU093 and SU056. Figure 1E provides a table representing the % inhibition values of etoposide, SU093, and SU056 in nerve (SH-SY5Y, N27) cells and HEK293 cells. Figure 1F shows a table of the cell cycle distribution of OVCAR8 cells, SKOV3 cells, and ID8 cells stained with propidium iodide (PI). Figure 1G is a graph showing the effects of SU093 and SU056 on apoptotic cell death. Figure 1H is a graph showing the results of the cell migration assay. [Figure 2] Figure 2A shows representative images of tumor regression in mice compared to controls after 42 days of drug treatment. Figure 2B is a graph showing tumor volume / mouse as a function of time. Figure 2C is a graph showing tumor weight / mouse at the end of the study. Figure 2D provides a graph of hepatotoxicity parameters at the end of 42 days, showing no significant difference between controls and SU093 and SU056. Figure 2E shows H&E stained images from a lung metastasis assay. Figure 2F provides a graph of the number of lung metastatic nodules. [Figure 3] Figure 3A provides a heatmap display of the thermal stability of 804 soluble proteins in ovarian cancer cells treated with the media DMSO (left) and SU056 (right). Figure 3B is a graph showing the density distribution of calculated protein Tm values in cells treated with SU056 and in the media. Figure 3C shows a graph showing the density distribution of Tm shift between SU056 treatment and media treatment. Figure 3D provides a scatter plot of calculated Tm in SU056 treatment and media treatment. Figure 3E shows the melting curves for six proteins with and without SU056 treatment. Figure 3F provides a table showing the change in melting temperature (Tm) for the top six proteins during SU056 treatment. [Figure 4] Figure 4A illustrates Western blot analyses performed on the top three targets identified by CETSA. Figure 4B provides subset images of immunohistochemistry of tumor samples from ID8 tumor xenograft studies. Figure 4C shows graphs of % inhibition in OC cells treated with SU056 and YB-1, respectively. Figure 4D shows a graph of YB-1 (IC50) for SU056 in OC cells. Figure 4E shows graphs illustrating YB-1 inhibition time-kinetics studies for the effect of SU056 on OC cell lines. [Figure 5]Figure 5A shows the structure of biotinylated SU056. Figure 5B illustrates a pull-down assay using biotinylated SU056. Figure 5C provides a representative sensogram for SU093. Figure 5D provides a representative sensogram for SU056. Figure 5E shows a Western blot analysis confirming YB-1 expression in transduced cells. Figure 5F shows an image demonstrating that the cellular effect of SU056 is dependent on YB-1 expression. Figure 5G provides a graph of IC50 values of SU056 for different transduced OVCAR8 cells expressing SC, YBX1 shRNA1, and YBX1 shRNA2. [Figure 6] Figure 6A illustrates the cycloheximide chase assay and a graph of the magnification change over time to determine the effect of SU056 on YB-1 protein stability. Figure 6B illustrates SDS-PAGE and Western blot analyses performed on YB-1, cell cycle markers, and apoptosis-related markers. Figures 6C and 6D show the enrichment of apoptotic and RNA degradation pathways observed in proteins whose abundance increased upon treatment with SU056. Figure 6E provides a graph of the enrichment of the spliceosome pathway observed in proteins whose abundance decreased upon treatment with SU056. [Figure 7]Figure 7A provides a table showing the sensitization effect of SU056 combined with paclitaxel treatment on the viability of OVCAR8 and SKOV3 cells. Figure 7B is a graph showing an Alexa Fluor-488 tagged paclitaxel efflux assay, demonstrating that co-treatment with SU056 inhibits paclitaxel efflux. Figure 7C shows SDS-PAGE gels for immunoblotting of YB-1 and MDR1. Medium (C), OVCAR8 cells treated with either paclitaxel, SU056, or paclitaxel + SU056. Figure 7D provides 10x magnification microscopic images of spheroids. Figure 7E provides a graph of spheroid formation quantified after 7 days of incubation. Figure 7F shows representative images of mice after 28 days of drug treatment, showing tumor regression compared to controls. Figure 7G is a graph showing tumor volume / mouse as a function of time. Figure 7H, tumor weight / mouse at the end of the study. I) Immunohistochemical staining. Tumor sections were stained with Ki67, and slides were scored for KI67 staining. The data shown are mean ± SD from 5 mice in each group. * P<0.05, ** P<0.01, *** P<0.001, compared to the respective control. [Figure 8] Figure 8A illustrates Western blot analysis of cell lysates from control-treated and SU056-treated cells, which were exposed to temperatures of 37°C and 53°C and analyzed for the expression of YB-1, TMSB10, and PSMB2. Figure 8B illustrates 10x magnification micrographs of cells imaged using a confocal microscope for mCherry-YB1 after 3 hours of treatment with SU056 (2.5 & 5 μM). Figure 8C shows a graph representing 2500 cells treated with SU056. [Figure 9] Figure 9 shows a graph illustrating the sensitization effect of SU056 on the viability of OVCAR8 and SKOV3 cells in combination with paclitaxel treatment. [Figure 10] Figure 10 shows a graph illustrating the pharmacokinetics of SU056. [Figure 11]Figure 11A provides a graph showing the growth inhibitory effect of SU056 as evaluated using the MTT assay. Figure 11B provides an image showing colony formation from cells treated with SU056 and incubated for an additional 7–10 days. Figure 11C illustrates a graph showing the number of colonies formed after SU056 treatment. Figure 11D provides a graph showing the effect of SU056 on the cell cycle distribution in TNBC cells. [Figure 12] Figure 12A shows SDS-PAGE and Western blot analysis of the inhibition of protein translation-related molecules by SU056 treatment in MDA-MB-231b cells. Figure 12B shows SDS-PAGE and Western blot analysis of the inhibition of protein translation-related molecules by SU056 treatment in MDA-MB-468 cells. Figure 12C shows SDS-PAGE and Western blot analysis of the inhibition of protein translation-related molecules by SU056 treatment in SUM159 cells. [Figure 13] Figure 13A shows a graph of tumor volume (MDA-MB-231) as a function of time. Figure 13B shows a graph of tumor weight (MDA-MB-231) at the end of the study. Figure 13C shows a graph of body weight (MDA-MB-231) as a function of time. Figure 13D shows a graph of tumor volume (MDA-MB-468) as a function of time. Figure 13E shows a graph of tumor weight (MDA-MB-468) at the end of the study. Figure 13F shows a graph of body weight (MDA-MB-468) as a function of time. Figure 13G provides a representative image of the tumor (MDA-MB-231) at the end of the study. Figure 13H provides a representative image of the tumor (MDA-MB-468) at the end of the study. Figure 13I shows a graph representing tumor volume (SUTI151-PDX) as a function of time. Figure 13J shows a graph representing tumor weight (SUTI151-PDX) at the end of the study. Figure 13K shows a graph representing body weight (SUTI151-PDX) as a function of time. [Figure 14]Figure 14A shows a graph of tumor volume (4T1) as a function of time in inhibition by SU056 in 4T1 tumor xenografts in BALB / c. Figure 14B shows a graph of tumor weight (4T1) at the end of the study. Figure 14C shows a graph of weight (4T1) as a function of time. Figure 14D provides a representative image of the tumor (4T1) at the end of the study. Figure 14E shows a graph of tumor volume (4T1) as a function of time. Figure 14F shows a graph of tumor weight (4T1) at the end of the study. Figure 14G shows a graph of weight (4T1) as a function of time. [Figure 15] Figure 15A shows a graph demonstrating the good tolerance of SU056 treatment in mice and rats, as reflected by changes in body weight in mice. Figure 15B shows a graph demonstrating the good tolerance of SU056 treatment in mice and rats, as reflected by changes in body weight in rats. Figure 15C shows a table of data demonstrating that SU056 treatment at different concentrations did not cause death in mice. Figure 15D shows a table of data demonstrating that SU056 treatment at different concentrations did not cause death in rats. Figure 15E shows a graph demonstrating that SU056 had an average half-life of 40 minutes. [Figure 16] Figure 16 shows the normalized expression levels of YBX1 in the illustrated cell lines. [Figure 17] Figure 17 shows SDS-PAGE and Western blot images demonstrating that SU056 treatment inhibited translation initiation factors in TNBC cells. [Figure 18] Figure 18 shows SDS-PAGE and Western blot images demonstrating that SU056 treatment inhibited translation initiation factors in TNBC cells. [Figure 19] Figure 19 shows SDS-PAGE and Western blot images demonstrating that SU056 treatment inhibited translation initiation factors in TNBC cells. [Modes for carrying out the invention]
[0014] Detailed description of the invention Under the above conditions, compounds in which R2 is F or CF3 and R1, R3, R4, and R5 are each H exhibit the same substitution pattern as when R4 is F or CF3 and R1, R2, R3, and R5 are each H, demonstrating the rotation of the phenyl ring. To consider a compound as having an F or CF3 group at R4 implies the condition that at least one of R1, R2, R3, and R5 is not H.
[0015] It is also understood that within the range of formula (I) described above, there are four additional distinct embodiments, each containing a compound of formula (Ia), formula (Ib), formula (Ic), or formula (Id), respectively. In each embodiment, all variables (including n, R1, R2, R3, R4, R5, and R6), if present, are as defined for formula (I), and the compound of formula (Ia) has the condition that if R2 is F or CF3, at least one of R1, R3, R4, and R5 is not H. TIFF2023552368000005.tif136128
[0016] Another embodiment includes compounds of formula (I) with a different definition than described above, wherein X, R1, R2, R3, R4, R5, and R6 are as defined and given above, and n is an integer independently selected in each case from the group 1, 2, 3, 4, and 5.
[0017] Another embodiment includes a compound of formula (I) with a different definition than described above, wherein X, R1, R2, R3, R4, R5, and R6 are as defined and given above, and n is an integer independently selected in each case from the groups 1, 2, 3, and 4.
[0018] Further embodiments include compounds of formula (I) with a different definition than described above, wherein X, R1, R2, R3, R4, R5, and R6 are as defined and given above, and n is an integer independently selected in each case from the groups 1, 2, and 3.
[0019] A further aspect includes a compound of formula (I) with different definitions, wherein X, R1, R2, R3, R4, R5, and R6 are as defined above and meet the conditions, and n is an integer independently selected in each case from the group of 2 and 3.
[0020] A further aspect includes a compound of formula (I) with different definitions, wherein X, R1, R2, R3, R4, R5, and R6 are as defined above and meet the conditions, and n is 2.
[0021] A further aspect includes a compound of formula (I) with different definitions, wherein X, R1, R2, R3, R4, R5, and R6 are as defined above and meet the conditions, and n is 3.
[0022] In each of the above aspects including a compound of formula (I), there is a further aspect where X, R1, R2, R3, R4, R5, and n are as defined for specific aspects, and R6 is H.
[0023] One aspect provides a compound of formula (II): TIFF2023552368000006.tif65128 or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, and R5 are each independently selected from the group consisting of H, F, C1-C4 fluoroalkyl, SF5, Cl, Br, I, OH, C1-C4 alkyl, C1-C4 alkoxy, CN, NO2, and OH; n is an integer independently selected in each case from the group of 1, 2, 3, 4, 5, and 6; R6 is selected from the group consisting of H, C1-C6 alkyl, C3-C6 cycloalkyl, -(CH2) n -C3-C6 cycloalkyl, 3-6 membered heterocycle, -(CH2) n -3-6 membered heterocycle, phenyl, and -(CH2) n -phenyl; the C1-C6 alkyl group is substituted with 0, 1, 2, 3, or 4 substituents selected from F, Cl, Br, I, OH, CN, NO2, and OH; C3-C6 cycloalkyl, -(CH2) n-C3-C6 cycloalkyl, 3-6 membered heterocycle, -(CH2) n -3- to 6-membered heterocycles, phenyl, and -(CH2) n -The phenyl group is substituted with 0, 1, 2, 3, or 4 substituents selected from C1-C3 alkyl, C1-C3 alkoxy, F, Cl, Br, I, OH, CN, NO2, and OH; However, at least one of R1, R2, R3, R4, and R5 is selected from the group consisting of F, C1-C4 fluoroalkyl, and SF5; However, if R2 is F or CF3, then at least one of R1, R3, R4, and R5 is not H.
[0024] Another embodiment includes a compound of formula (II) where R1, R2, R3, R4, R5, and R6 are as defined and conditioned above, and n is an integer independently selected in each case from the group 1, 2, 3, 4, and 5.
[0025] Another embodiment includes a compound of formula (II) where R1, R2, R3, R4, R5, and R6 are as defined and conditioned above, and n is an integer independently selected in each case from the groups 1, 2, 3, and 4.
[0026] Further embodiments include compounds of formula (II) where R1, R2, R3, R4, R5, and R6 are as defined and conditioned above, and n is an integer independently selected in each case from the groups 1, 2, and 3.
[0027] Further embodiments include compounds of formula (II) where R1, R2, R3, R4, R5, and R6 are as defined and conditioned above, and n is an integer independently selected in each case from groups 2 and 3.
[0028] Further embodiments include compounds of formula (II) where R1, R2, R3, R4, R5, and R6 are as defined and conditioned above, and n is 2.
[0029] Further embodiments include compounds of formula (II) where R1, R2, R3, R4, R5, and R6 are as defined and conditioned above, and n is 3.
[0030] In each of the above embodiments comprising the compound of formula (II), there exist further embodiments in which R1, R2, R3, R4, R5, and n are as defined for the specific embodiment, and R6 is H.
[0031] Further embodiments include compounds of formula (III): We provide TIFF2023552368000007.tif54128 or a pharmaceutically acceptable salt thereof. In the formula, n is an integer independently selected in each case from the groups 1, 2, 3, 4, 5, and 6; R1, R2, R3, R4, and R5 are each independently selected from the group consisting of H, F, C1-C4 fluoroalkyl, SF5, Cl, Br, I, OH, C1-C4 alkyl, C1-C4 alkoxy, CN, NO2, and OH; However, at least one of R1, R2, R3, R4, and R5 is selected from the group consisting of F, C1-C4 fluoroalkyl, and SF5; However, if R2 is F or CF3, then at least one of R1, R3, R4, and R5 is not H.
[0032] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein n is an integer independently selected in each case from the group 1, 2, 3, 4, 5, and 6; R1 is selected from the group F, C1-C4 fluoroalkyl, and SF5; and R2, R3, R4, and R5 are each independently selected from the group H, F, C1-C4 fluoroalkyl, SF5, Cl, Br, I, OH, C1-C4 alkyl, C1-C4 alkoxy, CN, NO2, and OH.
[0033] Another embodiment provides a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein n is an integer independently selected in each case from the group 1, 2, 3, 4, 5, and 6; R3 is selected from the group F, C1-C4 fluoroalkyl, and SF5; and R1, R2, R4, and R5 are each independently selected from the group H, F, C1-C4 fluoroalkyl, SF5, Cl, Br, I, OH, C1-C4 alkyl, C1-C4 alkoxy, CN, NO2, and OH.
[0034] Further aspects include: n is an integer independently selected in each case from the groups 1, 2, 3, 4, 5, and 6; R1, R2, R3, R4, and R5 are each independently selected from the group consisting of H, F, C1-C4 fluoroalkyl, SF5, Cl, Br, I, OH, C1-C4 alkyl, C1-C4 alkoxy, CN, NO2, and OH; The present invention provides a compound of formula (III) or a pharmaceutically acceptable salt thereof, wherein at least two of R1, R2, R3, R4, and R5 are selected from the group consisting of F, C1-C4 fluoroalkyl, and SF5.
[0035] Further embodiments provide compounds of formula (III) or pharmaceutically acceptable salts thereof. In the formula, n is an integer independently selected in each case from the group 1, 2, 3, 4, 5, and 6; R1, R2, R3, R4, and R5 are each independently selected from the group consisting of H, F, C1-C3 fluoroalkyl, SF5, Cl, Br, I, OH, C1-C4 alkyl, C1-C4 alkoxy, CN, NO2, and OH; However, at least two of R1, R2, R3, R4, and R5 are selected from the group of F, C1-C3 fluoroalkyls.
[0036] Further embodiments provide compounds of formula (III) or pharmaceutically acceptable salts thereof. In the formula, n is an integer independently selected in each case from the group 1, 2, 3, 4, 5, and 6; R1, R2, R3, R4, and R5 are each independently selected from the group consisting of H, F, CF3, SF5, Cl, Br, I, OH, C1-C4 alkyl, C1-C4 alkoxy, CN, NO2, and OH. However, at least two of R1, R2, R3, R4, and R5 are selected from the F and CF3 groups.
[0037] Further embodiments provide compounds of formula (III) or pharmaceutically acceptable salts thereof. In the formula, n is an integer independently selected in each case from the group 1, 2, 3, 4, 5, and 6; R1, R2, R3, R4, and R5 are each independently selected from the group consisting of H, F, CF3, SF5, Cl, Br, I, OH, C1-C4 alkyl, C1-C4 alkoxy, CN, NO2, and OH. However, at least two of R1, R2, R3, R4, and R5 are F.
[0038] Another embodiment includes a compound of formula (III) where R1, R2, R3, R4, and R5 are as defined and conditioned above, and n is an integer independently selected in each case from the group 1, 2, 3, 4, and 5.
[0039] Another embodiment includes a compound of formula (III) where R1, R2, R3, R4, and R5 are as defined and conditioned above, and n is an integer independently selected in each case from the groups 1, 2, 3, and 4.
[0040] Further embodiments include compounds of formula (III) where R1, R2, R3, R4, and R5 are as defined and conditioned above, and n is an integer independently selected in each case from the groups 1, 2, and 3.
[0041] Further embodiments include compounds of formula (III) such that R1, R2, R3, R4, and R5 are as defined and conditioned above, and n is an integer independently selected in each case from groups 2 and 3.
[0042] Further embodiments include compounds of formula (III) where R1, R2, R3, R4, and R5 are as defined and conditioned above, and n is 2.
[0043] Further embodiments include compounds of formula (III) where R1, R2, R3, R4, and R5 are as defined and conditioned above, and n is 3.
[0044] Pharmaceutical composition Pharmaceutical compositions are also provided that comprise a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable cocrystal, ester, solvate, hydrate, isomer, tautomer, isotope, polymorph, or prodrug, and a pharmaceutically acceptable carrier or excipient.
[0045] Treatment method Each of the following methods of treatment refers to the use of a compound of formula (I) or its pharmaceutically acceptable salts, pharmaceutically acceptable cocrystals, pharmaceutically acceptable esters, pharmaceutically acceptable solvates, hydrates, isomers (e.g., optical isomers, racemic compounds, or other mixtures thereof), tautomers, isotopes, polymorphs, and pharmaceutically acceptable prodrugs. It is understood that each method provides additional embodiments in which the compound used is of formula (Ia), formula (Ib), formula (Ic), formula (Id), formula (II), formula (III), SU056, etc., or their pharmaceutically acceptable salts, pharmaceutically acceptable cocrystals, esters, solvates, hydrates, isomers, tautomers, isotopes, polymorphs, or prodrugs.
[0046] A method is provided for inhibiting YB1 protein activity in a subject, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, pharmaceutically acceptable cocrystal, ester, solvate, hydrate, isomer, tautomer, isotope, polymorph, or prodrug thereof to a subject requiring such action.
[0047] A method is provided for inhibiting YB1 protein activity in a subject experiencing cancer, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable cocrystal, ester, solvate, hydrate, isomer, tautomer, isotope, polymorph, or prodrug to a subject in need thereof. In a different embodiment, the cancer experienced by the subject is selected from the group of gynecological cancers (e.g., ovarian cancer, endometrial cancer, fallopian tube cancer, and cervical cancer), breast cancer, lung cancer, prostate cancer, colorectal cancer, and gastric cancer.
[0048] Methods to inhibit YB1 protein activity have been shown to affect other cancers associated with YBX1 expression, such as acute myeloid leukemia (Zhou et al., Journal of Experimental & Clinical Cancer Research (2021) 40:353), renal cell carcinoma (Ruan et al., Oncogene (2020) 39: 6113-6128), bladder cancer (Xu et al., Oncotarget, 2017, Vol.8, No.39, pp.65946-65956), osteosarcoma (Fujiwara-Okada et al., British Journal of Cancer (2013) 108, pp.836-847), head and neck cancer (Kolk et al., British Journal of Cancer (2011) 105, pp.1864-1873), and nasopharyngeal cancer (Zhou et al., Experimental Cell Research 361 (2017)). It may be used in the procedures described in pp. 126-134 and Ban et al., Journal of Cancer 2021, Vol. 12(11), pp. 3315-3324.
[0049] A method is also provided for making cancer cells expressing the YB1 (YBX1) protein in a subject sensitive to treatment with an anticancer agent, comprising the step of administering a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt, pharmaceutically acceptable cocrystal, ester, solvate, hydrate, isomer, tautomer, isotope, polymorph, or prodrug in a subject requiring it. It is understood that separate methods for making each of the cancers referred to herein sensitive to their associated anticancer agents are included herein.
[0050] A method is also provided for making cancer cells expressing the YB1 (YBX1) protein in a subject sensitive to radiotherapy, comprising the step of administering a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt, pharmaceutically acceptable cocrystal, ester, solvate, hydrate, isomer, tautomer, isotope, polymorph, or prodrug in a subject requiring it. It is understood that separate methods for making each of the cancers referred to herein sensitive to radiotherapy are included herein.
[0051] It is also understood that a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof may be administered concurrently with an additional anticancer agent or radiation in a single regimen. In other embodiments, a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof may be administered in a single dose or regimen to a subject in need, prior to subsequent administration of a specified anticancer agent and / or radiation therapy.
[0052] In some embodiments, a compound of formula (I) or a pharmaceutically acceptable salt thereof may be administered for an initial period, for example, 1 to 7 days, thereafter, a specified anticancer agent and / or radiotherapy may be administered sequentially to the subject in need.
[0053] In a further embodiment, a compound of formula (I) or a pharmaceutically acceptable salt thereof, along with one or more designated anticancer agents and / or radiotherapys, may be administered to a subject in need in repeated consecutive periods of 1 to 14 days, with or without a refractory period between each set of administrations that does not include any treatment.
[0054] In another embodiment, the compound of formula (I) may be administered for an initial period, for example, 1 to 7 days, and thereafter, in a second period, both a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically effective amount of a designated anticancer agent and / or radiotherapy may be administered simultaneously to the subject in need.
[0055] In a different embodiment, cancer cells expressing the YB1 (YBX1) protein in subjects to be made sensitive to the treatment described herein are selected from the group of gynecological cancers (e.g., ovarian cancer, endometrial cancer, fallopian tube cancer, and cervical cancer), leukemia, lymphoma, renal cancer, bladder cancer, pancreatic cancer, head and neck cancer, breast cancer (e.g., trinegative, ER-negative, ER-positive breast cancer, and progesterone-positive), lung cancer, ovarian cancer, prostate cancer, colorectal cancer, gastric cancer, and neurocarcinoma (e.g., glioma).
[0056] gynecological cancer A method is provided for treating gynecological cancers expressing the YB1 (YBX1) protein in a subject, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0057] A method for treating gynecological cancers expressing the YB1 (YBX1) protein in a subject is also provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically effective amount of an mTOR inhibitor or a pharmaceutically acceptable salt thereof to a subject in need. In some embodiments, the mTOR inhibitor is selected from the group of sirolimus, everolimus, defololimus, and temsirolimus.
[0058] A method is also provided for enhancing the effect of an anticancer agent in a subject experiencing gynecological cancer expressing the YB1 (YBX1) protein, comprising the step of administering a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need. In some embodiments, treatment with the compound of formula (I) makes gynecological cancer cells expressing the YB1 (YBX1) protein in the subject sensitive to treatment with the anticancer agent.
[0059] In some aspects, anticancer agents used to treat gynecological cancers are phosphoinositide 3-kinase (PI3K) / protein kinase B (Akt) inhibitors or antagonists.
[0060] In some embodiments, the gynecological cancer expressing the YB1 (YBX1) protein to be treated is ovarian cancer. In other embodiments, the gynecological cancer to be treated is endometrial cancer. In yet another embodiment, the gynecological cancer to be treated is cervical cancer.
[0061] Therefore, (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of cisplatin or a pharmaceutically acceptable salt thereof A method for treating ovarian cancer expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the substance to a subject that requires it.
[0062] Therefore, (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of a taxane compound or a pharmaceutically acceptable salt thereof A method for treating ovarian cancer expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the substance to a subject that requires it.
[0063] In some embodiments, the taxane compound used in the method of treating gynecological cancers expressing the YB1 (YBX1) protein described herein is selected from the group of paclitaxel, docetaxel, and cabazitaxel.
[0064] For each method of making cancer cells expressing the YB1(YBX1) protein in a subject sensitive to anticancer drug and / or radiotherapy, or inhibiting YB1 protein activity in a cancer-experiencing subject, there exists a corresponding method comprising: a first step of detecting the presence or absence of expressed YB1(YBX1) protein in a sample of cancer cells; and, if it is determined that the YB1(YBX1) protein is present in the sample cells, treating the cancer-experiencing subject described in each method with a pharmaceutically effective amount of the compound of formula (I) or any pharmaceutically acceptable salt, pharmaceutically acceptable cocrystal, ester, solvate, hydrate, isomer, tautomer, isotope, polymorph, or prodrug, and any other agent as indicated by the specific method.
[0065] As a non-limiting example, (a) A step of determining the presence or absence of expressed YB1 protein in ovarian cancer tumor samples collected from subjects requiring it, and (b) If it is determined that the expressed YB1 protein is present in the ovarian cancer tumor sample, (i) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (ii) A pharmaceutically effective amount of a taxane compound or a pharmaceutically acceptable salt thereof The process of administering it to the target that needs it. A method for treating ovarian cancers expressing the YB1 (YBX1) protein in the subject is also provided.
[0066] Therefore, (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of a taxane compound or a pharmaceutically acceptable salt thereof A method for treating fallopian tube cancer (carcinoma) expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to the subject in need.
[0067] Therefore, (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; (b) a pharmaceutically effective amount of a taxane compound or a pharmaceutically acceptable salt thereof; and (c) A pharmaceutically effective amount of carboplatin or a pharmaceutically acceptable salt thereof A method for treating fallopian tube cancer (tubal cancer) expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the substance to a subject that requires it.
[0068] In some embodiments, the taxane compound used in a method for treating fallopian tube cancer is selected from the group consisting of paclitaxel, albumin-conjugated paclitaxel, docetaxel, and cabazitaxel.
[0069] prostate cancer A method for treating prostate cancer expressing the YB1 (YBX1) protein in a subject is also provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0070] A method for inhibiting prostate cancer metastases expressing the YB1 (YBX1) protein in a subject is further provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0071] A method is further provided for making prostate cancer expressing the YB1 (YBX1) protein in a subject sensitive to treatment with an anticancer agent, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0072] In some embodiments, administration of a compound of formula (I) makes prostate cancer expressing the YB1 (YBX1) protein in a subject susceptible to treatment with a taxane anticancer agent. In some embodiments, the taxane anticancer agent is selected from the group of paclitaxel, docetaxel, and cabazitaxel, or a pharmaceutically acceptable salt thereof.
[0073] Therefore, (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; (b) A pharmaceutically effective amount of a taxane compound selected from the group consisting of paclitaxel, docetaxel, and cabazitaxel, or a pharmaceutically acceptable salt thereof. A method for treating prostate cancer expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to a subject that requires it.
[0074] In some embodiments, administration of a compound of formula (I) makes prostate cancer expressing the YB1 (YBX1) protein in a subject sensitive to treatment with an androgen receptor inhibitor anticancer agent. In some embodiments, the androgen receptor inhibitor is selected from the group consisting of apalutamide, enzalutamide, darolutamide, and abiraterone acetate.
[0075] Therefore, (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of an androgen receptor inhibitor compound selected from the group consisting of apalutamide, enzalutamide, darolutamide, and abiraterone acetate, or a pharmaceutically acceptable salt thereof. A method for treating prostate cancer expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to a subject that requires it.
[0076] In some embodiments, apalutamide is administered to subjects requiring it at a daily dose of approximately 100 mg to approximately 300 mg. In some embodiments, apalutamide is administered at a daily dose of approximately 240 mg.
[0077] In some embodiments, the anticancer agent is a luteinizing hormone-releasing hormone (LHRH) agonist. In some embodiments, the LHRH agonist is selected from the group consisting of leuprolide / leuprorelin, goserelin, triptorelin, buserelin, and histrelin.
[0078] Therefore, (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of a luteinizing hormone-releasing hormone (LHRH) agonist compound selected from the group consisting of leuprolide / leuprorelin, goserelin, triptorelin, buserelin, and histrelin, or a pharmaceutically acceptable salt thereof. A method for treating prostate cancer expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to a subject that requires it.
[0079] In other embodiments, the anticancer agent is a luteinizing hormone-releasing hormone (LHRH) antagonist. In some embodiments, the LHRH agonist is degarelix.
[0080] Therefore, (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of degarelix or a pharmaceutically acceptable salt thereof A method for treating prostate cancer in a subject is also provided, which includes the step of administering the substance to a subject in need.
[0081] In other embodiments, the anticancer agent is an antiandrogenic agent. In some embodiments, the antiandrogenic agent is selected from the group of flutamide, bicalutamide, and nilutamide.
[0082] Therefore, (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of an antiandrogen compound selected from the group of flutamide, bicalutamide, and niltamide, or a pharmaceutically acceptable salt thereof. A method for treating prostate cancer expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to a subject that requires it.
[0083] In some aspects of the methods herein for treating prostate cancer and / or inhibiting prostate cancer metastasis, the prostate cancer is androgen-independent prostate cancer. In other aspects, the prostate cancer is castration-sensitive prostate cancer. In other aspects, the prostate cancer is metastatic castration-sensitive prostate cancer. In further aspects, the prostate cancer expressing the YB1 (YBX1) protein to be treated is non-metastatic castration-resistant prostate cancer. In other aspects, the prostate cancer is hormone-refractory prostate cancer (HRPC).
[0084] melanoma A method for treating melanoma expressing the YB1 (YBX1) protein in a subject is also provided, comprising the step of administering a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0085] A method for inhibiting melanoma metastasis expressing the YB1 (YBX1) protein in a subject is further provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0086] A method is further provided for making melanoma cells expressing the YB1 (YBX1) protein in a subject sensitive to treatment with an anticancer agent, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0087] Therefore, (c) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (d) A PD-1 inhibitor selected from the group consisting of pembrolizumab and nivolumab in a pharmaceutically effective dose, or a pharmaceutically acceptable salt thereof. A method for treating melanoma expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the substance to a subject that requires it.
[0088] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of atezolizumab or a pharmaceutically acceptable salt thereof A method for treating melanoma expressing the YB1 (YBX1) protein in a subject is further provided, comprising the step of administering the substance to a subject in need.
[0089] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; (b) a pharmaceutically effective amount of atezolizumab or a pharmaceutically acceptable salt thereof; and (c) A third drug selected from the group consisting of cobimetinib and vemurafenib in a pharmaceutically effective amount, or a pharmaceutically acceptable salt thereof. A method for treating melanoma expressing the YB1 (YBX1) protein in a subject is further provided, comprising the step of administering the substance to a subject in need.
[0090] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of a CTLA-4 inhibitor (e.g., ipilimumab) A method for treating melanoma expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the substance to a subject that requires it.
[0091] Therefore, (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of interleukin-2 (IL-2) A method for treating melanoma expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the substance to a subject that requires it.
[0092] Cisplatin resistance YB-1 expression or overexpression has also been associated with resistance to cisplatin treatment in several cancers, such as breast cancer, bladder cancer, and ovarian cancer.
[0093] In some embodiments, the treated breast cancer is refractory to endocrine agents, such as selective estrogen receptor modulators (SERMs), such as tamoxifen and toremifene. In some embodiments, the breast cancer is refractory to selective estrogen receptor degraders (SERDs), such as fulvestrant and elastrant. In other embodiments, the treated breast cancer is refractory to aromatase inhibitors, such as letrozole, anastrozole, exemestane, and testolactone.
[0094] A method for making cancer expressing the YB1 (YBX1) protein in a subject susceptible to cisplatin treatment is provided herein, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject requiring such treatment.
[0095] A method for making cancer expressing the YB1 (YBX1) protein in a subject susceptible to treatment with a taxane compound is provided herein, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject requiring such treatment.
[0096] breast cancer A method for treating breast cancer expressing the YB1 (YBX1) protein in a subject is also provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0097] A method for inhibiting breast cancer metastases expressing the YB1 (YBX1) protein in a subject is further provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0098] Further provided is a method for making breast cancer cells expressing the YB1 (YBX1) protein in a subject sensitive to treatment with anticancer agents, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need. In some embodiments, the method makes breast cancer cells expressing the YB1 (YBX1) protein in a subject in need sensitive to treatment with one or more agents selected from the group of anthracyclines (e.g., doxorubicin, PEGylated liposomal doxorubicin, and epirubicin), taxane compounds (e.g., paclitaxel, albumin-conjugated paclitaxel, docetaxel, and cabazitaxel), 5-fluorouracil, capecitabine, cyclophosphamide, vinarelbin, gemcitabine, ixabepyrone, eribulin, and platinum agents (e.g., carboplatin and cisplatin). In another embodiment, the method makes breast cancer cells expressing YB1 (YBX1) sensitive to radiotherapy treatment.
[0099] One aspect is, (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of one or more anticancer agents selected from the group of doxorubicin, PEGylated liposomal doxorubicin, epirubicin, paclitaxel, docetaxel, 5-fluorouracil, capecitabine, cyclophosphamide, and carboplatin, or a pharmaceutically acceptable salt thereof. The present invention provides a method for treating breast cancer expressing the YB1 (YBX1) protein in a subject, comprising the step of administering the substance to a subject that requires it.
[0100] Another aspect is, (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of one or more anticancer agents selected from the group of paclitaxel, albumin-conjugated paclitaxel, docetaxel, doxorubicin, PEGylated liposomal doxorubicin, epirubicin, cisplatin, carboplatin, vinorelbine, capecitabine, gemcitabine, ixabepyrone, and eribulin, or a pharmaceutically acceptable salt thereof. The present invention provides a method for treating breast cancer expressing the YB1 (YBX1) protein in a subject, comprising the step of administering the substance to a subject that requires it.
[0101] colorectal cancer A method for treating colorectal cancer expressing the YB1 (YBX1) protein in a subject is also provided, comprising the step of administering a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0102] A method for inhibiting colorectal cancer metastases expressing the YB1 (YBX1) protein in a subject is further provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0103] A method for making colorectal cancer cells expressing the YB1 (YBX1) protein in a subject sensitive to treatment with an anticancer agent is further provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0104] Therefore, (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of an anticancer agent selected from the group consisting of 5-fluorouracil, capecitabine, irinotecan, oxaliplatin, and trifluridine and tipiracil, or a pharmaceutically acceptable salt thereof. A method for treating colorectal cancer expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the substance to a subject that requires it.
[0105] bladder cancer A method for treating bladder cancer expressing the YB1 (YBX1) protein in a subject is also provided, comprising the step of administering a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0106] A method for inhibiting bladder cancer metastases expressing the YB1 (YBX1) protein in a subject is further provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0107] A method is further provided for making bladder cancer cells expressing the YB1 (YBX1) protein in a subject sensitive to treatment with an anticancer agent, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0108] (d) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; (e) a pharmaceutically effective amount of an anticancer agent selected from the group consisting of cisplatin, cisplatin and 5-fluorouracil, and mitomycin and 5-fluorouracil, or a pharmaceutically acceptable salt thereof; (f) A therapeutically effective dose of radiation A method is provided for treating bladder cancer expressing the YB1 (YBX1) protein in a subject, comprising the step of administering the YB1 protein to a subject that requires it.
[0109] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically effective amount (i) Gemcitabine and cisplatin; (ii) Dose-dense methotrexate, vinblastine, doxorubicin (adriamycin), and cisplatin (DDMVAC); (iii) cisplatin, methotrexate, and vinblastine (CMV); and (iv) Gemcitabine and paclitaxel Anticancer agents selected from the group A method for treating bladder cancer expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to a subject that requires it.
[0110] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; (b) A pharmaceutically effective amount of an anticancer agent selected from the group consisting of docetaxel, paclitaxel, doxorubicin, methotrexate, ifosfamide, and pemetrexed, or a pharmaceutically acceptable salt thereof. A method for treating bladder cancer expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to a subject that requires it.
[0111] Liver cancer A method for treating liver cancer expressing the YB1 (YBX1) protein in a subject is also provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0112] A method for inhibiting liver cancer metastases expressing the YB1 (YBX1) protein in a subject is further provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0113] A method is further provided for making liver cancer cells expressing the YB1 (YBX1) protein in a subject sensitive to treatment with an anticancer agent, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0114] Therefore, (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of an anticancer agent selected from the group consisting of gemcitabine, oxaliplatin, cisplatin, doxorubicin, 5-fluorouracil, capecitabine, and mitoxantrone, or a pharmaceutically acceptable salt thereof. A method for treating liver cancer expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the substance to a subject that requires it.
[0115] lung cancer A method for treating small cell lung cancer expressing the YB1 (YBX1) protein in a subject is also provided, comprising the step of administering a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0116] A method for inhibiting small cell lung cancer metastases expressing the YB1 (YBX1) protein in a subject is further provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0117] A method is further provided for making small cell lung cancer cells expressing the YB1 (YBX1) protein in a subject sensitive to treatment with an anticancer agent, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0118] Therefore, (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) an anticancer agent selected from the group consisting of cisplatin and etoposide, carboplatin and etoposide, cisplatin and irinotecan, and carboplatin and irinotecan in pharmaceutically effective amounts, or a pharmaceutically acceptable salt thereof. A method for treating small cell lung cancer expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the substance to a subject that requires it.
[0119] A method for treating non-small cell lung cancer expressing the YB1 (YBX1) protein in a subject is also provided, comprising the step of administering a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0120] A method for inhibiting non-small cell lung cancer metastases expressing the YB1 (YBX1) protein in a subject is further provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0121] A method is further provided for making non-small cell lung cancer cells expressing the YB1 (YBX1) protein in a subject sensitive to treatment with an anticancer agent, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0122] Therefore, (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A method for treating non-small cell lung cancer expressing the YB1 (YBX1) protein in a subject is also provided, comprising the step of administering to a subject in need one or more anticancer agents selected from the group of cisplatin, carboplatin, paclitaxel, albumin-conjugated paclitaxel, docetaxel, gemcitabine, vinarelbin, etoposide, and premetrexed, or a pharmaceutically acceptable salt thereof.
[0123] Multiple myeloma A method for treating multiple myeloma expressing the YB1 (YBX1) protein in a subject is also provided, comprising the step of administering a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0124] A method for inhibiting multiple myeloma metastases expressing the YB1 (YBX1) protein in a subject is further provided, comprising the step of administering a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0125] A method for making multiple myeloma cells expressing the YB1 (YBX1) protein in a subject susceptible to treatment with an anticancer agent is further provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0126] Therefore, (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of an anticancer agent selected from the group consisting of melphalan, vincristine, cyclophosphamide, etoposide, doxorubicin, liposomal doxorubicin, and bendamustine, or a pharmaceutically acceptable salt thereof. A method for treating multiple myeloma expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to the subject in need.
[0127] Soft tissue sarcoma Methods for treating soft tissue sarcomas expressing the YB1 (YBX1) protein, such as angiosarcoma, dermatofibrosarcoma protuberans, episarcoma, gastrointestinal stromal tumors (GIST), Kaposi's sarcoma, leiomyosarcoma, liposarcoma, malignant peripheral nerve sheath tumors, myxofibrosarcoma, rhabdomyosarcoma, solitary fibrous tumors, synovial sarcoma, and undifferentiated pleomorphic sarcoma, are also provided herein.
[0128] A method for treating a soft tissue sarcoma expressing the YB1(YBX1) protein, such as a fibrosarcoma expressing the YB1(YBX1) protein, is also provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0129] A method for inhibiting a soft tissue sarcoma expressing the YB1(YBX1) protein, such as a fibrosarcoma expressing the YB1(YBX1) protein, is further provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0130] A method is further provided for making soft tissue sarcoma cells expressing the YB1(YBX1) protein, such as fibrosarcoma cells expressing the YB1(YBX1) protein, sensitive to treatment with an anticancer agent, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0131] Therefore, (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of one or more anticancer agents selected from the group of ifosfamide, doxorubicin, dacarbazine (DTIC), epirubicin, temozolomide, docetaxel, gemcitabine, vinorelbine, trabectedin, and eribulin, or a pharmaceutically acceptable salt thereof. A method for treating soft tissue sarcomas expressing the YB1 (YBX1) protein, such as fibrosarcomas expressing the YB1 (YBX1) protein, is also provided, which includes the step of administering the YB1 (YBX1) protein to a subject that requires it.
[0132] In some embodiments, when the anticancer agent ifosfamide is used, the drug mesna is also provided to protect the bladder from the toxic effects of ifosfamide. In other embodiments, the anticancer agent is a combination of mesna, adriamycin [doxorubicin], ifosfamide, and dacarbazine, sometimes referred to by the acronym MAID. In other embodiments, the anticancer agent is a combination of adriamycin [doxorubicin], ifosfamide, and mesna, sometimes referred to by the acronym AIM. In some embodiments, in the method of treating soft tissue sarcoma described herein, the anticancer agent is administered to the subject in need using local (isolated) limb perfusion.
[0133] Osteosarcoma: A method for treating osteosarcoma expressing the YB1 (YBX1) protein in a subject is also provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0134] A method for inhibiting osteosarcoma expressing the YB1 (YBX1) protein in a subject is further provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0135] A method for making osteosarcoma cells expressing the YB1 (YBX1) protein in a subject sensitive to treatment with an anticancer agent is further provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0136] Therefore, (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of one or more anticancer agents selected from the group consisting of methotrexate, doxorubicin, cisplatin, carboplatin, ifosfamide, cyclophosphamide, etoposide, and gemcitabine, or a pharmaceutically acceptable salt thereof. A method for treating osteosarcoma expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the substance to a subject that requires it.
[0137] In some embodiments, the anticancer agent in the treatment of osteosarcoma expressing the YB1 (YBX1) protein is a combination of high-dose methotrexate, doxorubicin, and cisplatin (MAP regimen). In other embodiments, a combination of doxorubicin and cisplatin is administered. In other embodiments, a combination of ifosfamide and etoposide is used. In yet another embodiment, a combination of ifosfamide, epirubicin, and either cisplatin or carboplatin is administered.
[0138] Ewing's sarcoma A method for treating Ewing sarcoma expressing the YB1 (YBX1) protein in a subject is also provided, comprising the step of administering a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0139] A method for inhibiting Ewing sarcoma expressing the YB1 (YBX1) protein in a subject is further provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0140] A method is further provided for making Ewing sarcoma cells expressing the YB1 (YBX1) protein in a subject sensitive to treatment with an anticancer agent, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0141] Therefore, (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of one or more anticancer agents selected from the group consisting of cyclophosphamide, doxorubicin, etoposide, ifosfamide, and vincristine, or a pharmaceutically acceptable salt thereof. A method for treating Ewing sarcoma expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the substance to a subject that requires it.
[0142] In some embodiments, a method for treating Ewing sarcoma expressing the YB1 (YBX1) protein involves a combination of vincristine, doxorubicin, and cyclophosphamide alternating with ifosfamide and etoposide, and this regimen is called VDC / IE.
[0143] stomach cancer A method for treating gastric cancer (stomach cancer) expressing the YB1 (YBX1) protein in a subject is also provided, comprising the step of administering a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0144] A method for inhibiting gastric cancer expressing the YB1 (YBX1) protein in a subject is further provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0145] A method is further provided for making gastric cancer cells expressing the YB1 (YBX1) protein in a subject sensitive to treatment with an anticancer agent, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0146] Therefore, (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) One or more anticancer agents selected from the group consisting of 5-fluorouracil, capecitabine, carboplatin, cisplatin, docetaxel, epirubicin, irinotecan, oxaliplatin, paclitaxel, and trifluridine + tipracil (LONSURF®), or a pharmaceutically acceptable salt thereof, in a pharmaceutically effective amount. A method for treating gastric cancer expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the substance to a subject that requires it.
[0147] In some embodiments, in a method for treating gastric cancer expressing the YB1 (YBX1) protein, the anticancer agent is a combination of epirubicin, cisplatin, and 5-fluorouracil, sometimes referred to by the acronym ECF. In other embodiments, a combination of docetaxel or paclitaxel and either 5-FU or capecitabine, sometimes combined with radiation. In yet another embodiment, cisplatin is administered with either 5-FU or capecitabine, and may be combined with radiation. In yet another embodiment, paclitaxel and carboplatin are administered, and may be combined with radiation. In yet another embodiment, a combination of docetaxel, cisplatin, and 5-fluorouracil (DCF) is administered. In yet another embodiment, irinotecan is administered with cisplatin, 5-fluorouracil, or capecitabine. In yet another embodiment, oxaliplatin is administered with 5-fluorouracil or capecitabine. In yet another embodiment, trifluridine + tipracil (LONSURF®) is given.
[0148] Glioblastoma A method for treating glioblastoma polymorphism (GBM or glioblastoma) expressing the YB1 (YBX1) protein in a subject is also provided, comprising the step of administering a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0149] A method for inhibiting glioblastoma expressing the YB1 (YBX1) protein in a subject is further provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0150] A method is further provided for making glioblastoma cells expressing the YB1 (YBX1) protein in a subject sensitive to treatment with an anticancer agent, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0151] Therefore, (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) One or more anticancer agents selected from the group consisting of temozolomide, bevacizumab, lomustine, carmustine, fluzoparil, pembrolizumab, nivolumab, ipilimumab, anlotinib, glasdevib, and bavituximab, or their pharmaceutically acceptable salts, in pharmaceutically effective amounts. A method for treating glioblastoma expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the substance to a subject that requires it.
[0152] In some embodiments, the glioblastoma in the above method is a pediatric glioblastoma expressing the YB1(YBX1) protein. In some embodiments, the glioblastoma is a primary glioblastoma expressing the YB1(YBX1) protein. In other embodiments, it is a secondary glioblastoma expressing the YB1(YBX1) protein.
[0153] head and neck cancer In this specification, “head and neck cancer” refers to any cancer of the oral cavity, throat (pharynx, e.g., nasopharynx, oropharynx, and hypopharynx), larynx, sinuses, nasal cavity, and salivary glands. Head and neck cancers include hypopharyngeal cancer, laryngeal cancer, lip and oral cavity cancer, metastatic cervical squamous cell carcinoma, nasopharyngeal cancer, oropharyngeal cancer, sinus and nasal cavity cancer, and salivary gland cancer. For each method of treating head and neck cancer described herein, it is understood that a corresponding method for each of the head and neck cancers listed in this paragraph is also disclosed.
[0154] A method for treating head and neck cancer expressing the YB1 (YBX1) protein in a subject is also provided, comprising the step of administering a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0155] A method for inhibiting head and neck cancer metastases expressing the YB1 (YBX1) protein in a subject is further provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0156] A method is further provided for making head and neck cancer expressing the YB1 (YBX1) protein in a subject susceptible to treatment with an anticancer agent, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0157] In some embodiments relating to the treatment of head and neck cancer expressing YB1 (YBX1), the anticancer agent used to treat the subject is radiotherapy. In some embodiments, the radiation used is external beam radiation therapy. In some embodiments, the treatment includes administering a pharmaceutically effective amount of one or more EGFR inhibitors to a subject in need. Other embodiments relate to administering a pharmaceutically effective amount of larotrectinib (Vitrakvi) and / or larotrectinib to a subject in need.
[0158] Other methods for treating head and neck cancer include the use of immunotherapy, for example, the administration of pharmaceutically effective amounts of pembrolizumab and / or nivolumab to subjects who need it.
[0159] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of an anticancer agent selected from the group consisting of paclitaxel, docetaxel, cisplatin, carboplatin, 5-fluorouracil, methotrexate, and capecitabine, or a pharmaceutically acceptable salt thereof. A method for treating head and neck cancer expressing the YB1 (YBX1) protein in a subject is provided, comprising the step of administering the YB1 (YBX1) protein to a subject in need.
[0160] Therefore, (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of a taxane compound selected from the group consisting of paclitaxel and docetaxel, or a pharmaceutically acceptable salt thereof. A method for treating head and neck cancer expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to a subject that requires it.
[0161] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of cisplatin or a pharmaceutically acceptable salt thereof A method for treating head and neck cancer expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to a subject that requires it.
[0162] In some aspects, cisplatin is delivered three times at 3-week intervals at approximately 20 mg / m². 2 ~about 100mg / m 2 It is administered in that dose to those who need it.
[0163] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically effective amount of carboplatin or a pharmaceutically acceptable salt thereof; and (c) A drug selected from the group consisting of 5-fluorouracil (5FU) and cetuximab in pharmaceutically effective amounts. A method for treating head and neck cancer expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to a subject that requires it.
[0164] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically effective amount of cisplatin or a pharmaceutically acceptable salt thereof; as well (c) A drug selected from the group consisting of 5-fluorouracil (5FU) and cetuximab in pharmaceutically effective amounts. A method for treating head and neck cancer expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to a subject that requires it.
[0165] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically effective amount of cisplatin or a pharmaceutically acceptable salt thereof; and (c) A pharmaceutically effective amount of paclitaxel or a pharmaceutically acceptable salt thereof A method for treating head and neck cancer expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to a subject that requires it.
[0166] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically effective amount of carboplatin or a pharmaceutically acceptable salt thereof; and (c) A pharmaceutically effective amount of paclitaxel or a pharmaceutically acceptable salt thereof A method for treating head and neck cancer expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to a subject that requires it.
[0167] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically effective amount of hydroxyurea or a pharmaceutically acceptable salt thereof; and (c) A drug selected from the group consisting of 5-fluorouracil (5FU) and cetuximab in pharmaceutically effective amounts. A method for treating head and neck cancer expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to a subject that requires it.
[0168] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically effective amount of hydroxyurea or a pharmaceutically acceptable salt thereof; and (c) A drug selected from the group consisting of carboplatin, doxorubicin, epirubicin, paclitaxel, docetaxel, gemcitabine, bleomycin, and methotrexate in a pharmaceutically effective amount. A method for treating nasopharyngeal carcinoma expressing the YB1 (YBX1) protein in a subject is further provided, comprising the step of administering the YB1 (YBX1) protein to a subject in need.
[0169] Pancreatic cancer A method for treating pancreatic cancer expressing the YB1 (YBX1) protein in a subject is provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0170] A method for inhibiting pancreatic cancer metastases expressing the YB1 (YBX1) protein in a subject is further provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0171] A method is further provided for making pancreatic cancer expressing the YB1 (YBX1) protein in a subject sensitive to treatment with an anticancer agent, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0172] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of one or more anticancer agents selected from gemcitabine, 5-fluorouracil, oxaliplatin, paclitaxel, albumin-conjugated paclitaxel, docetaxel, capecitabine, cisplatin, and irinotecan, or a pharmaceutically acceptable salt thereof. A method for treating pancreatic cancer expressing the YB1 (YBX1) protein in a subject is provided, comprising the step of administering the substance to a subject in need.
[0173] Neurocellular carcinoma Compounds of formula (I) may also be used to treat and / or make sensitive to neuronal carcinomas (cancers of the brain and spinal cord), such as medulloblastoma, glioblastoma multiforme (GBM), astrocytoma (anaplastic astrocytoma and pilocytic astrocytoma), ependymoma, and oligodendroglioma. It is understood that each of the following methods for treating neuronal carcinoma or making neuronal carcinoma sensitive to the treatments described herein includes separate methods for each type of neuronal carcinoma listed in this paragraph.
[0174] A method is provided for treating neuronal cancer expressing the YB1 (YBX1) protein in a subject, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0175] A method for inhibiting YB1 (YBX1) protein-expressing neuronal cancer metastases in a subject is further provided, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0176] A method is further provided for making neuronal cancer expressing the YB1 (YBX1) protein in a subject sensitive to treatment with an anticancer agent, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need.
[0177] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of one or more anticancer agents selected from the group of carboplatin, carmustine (BCNU), cisplatin, irinotecan, cyclophosphamide, etoposide, lomustine, methotrexate, procarbazine, temozolomide, and vincristine, or a pharmaceutically acceptable salt thereof. A method is provided for treating neuronal cancer expressing the YB1 (YBX1) protein in a subject, comprising the step of administering the YB1 (YBX1) protein to a subject that requires it.
[0178] In some embodiments, a pharmaceutically effective amount of carmustine administered to a subject requiring it is in the form of a carmustine wafer or indwelling agent, such as the GLIADEL® wafer (carmustine indwelling agent) product available from Arbor Pharmaceuticals, LLC.
[0179] leukemia The methods of the present invention also include methods for treating leukemias, such as acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic (or lymphoid) leukemia (ALL), and chronic lymphocytic leukemia (CLL), wherein the leukemia cells express the YB-1 protein. It is understood that separate corresponding methods are understood for each of the leukemias mentioned herein (AML, CML, ALL, and CLL) for the treatment of leukemia or for sensitivity to treatment of leukemia.
[0180] Further provided is a method for making leukemia cells expressing the YB1 (YBX1) protein in a subject sensitive to treatment with an anticancer agent, comprising the step of administering a pharmaceutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof to a subject in need. In some embodiments, the anticancer agent used to treat the subject is radiotherapy.
[0181] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) an anthracycline drug selected from the group of daunorubicin and idarubicin in pharmaceutically effective amounts or a pharmaceutically acceptable salt thereof; (c) A pharmaceutically effective amount of cytarabine or a pharmaceutically acceptable salt thereof A method for treating acute myeloid leukemia expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to the subject in need.
[0182] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of one or more anticancer agents selected from the group consisting of cladribine (2-CdA), fludarabine, mitoxantrone, etoposide, 6-thioguanine, hydroxyurea, prednisone, detamexazone, methotrexate, 6-mercaptopurine, azacitidine, and decitabine, or a pharmaceutically acceptable salt thereof. A method for treating acute myeloid leukemia expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to the subject in need.
[0183] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) One or more anticancer agents selected from the group consisting of hydroxyurea, cytarabine (Ara-C), busulfan, cyclophosphamide (CYTOXAN®), and vincristine (ONCOVIN®), or pharmaceutically acceptable salts thereof, in pharmaceutically effective amounts. A method for treating chronic myeloid leukemia expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to the subject in need.
[0184] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of one or more tyrosine kinase inhibitor anticancer agents selected from the group consisting of imatinib (GLEEVEC®), dasatinib (SPRYCEL®), nilotinib (TASIGNA®), bosutinib (BOSULIF®), ponatinib (ICLUSIG®), and aciminib (SCEMBLIX®), or a pharmaceutically acceptable salt thereof. A method for treating chronic myeloid leukemia expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to the subject in need.
[0185] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of interferon-alpha or a pharmaceutically acceptable salt thereof A method for treating chronic myeloid leukemia expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to the subject in need.
[0186] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of one or more anticancer agents selected from the group consisting of vincristine, dexamethasone, imatinib, prednisone, doxorubicin, and daunorubicin, or a pharmaceutically acceptable salt thereof. A method for treating acute lymphoblastic leukemia expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to a subject in need.
[0187] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) One or more anticancer agents selected from the group consisting of methotrexate, 6-mercaptopurine, vincristine, prednisone, and imatinib, or their pharmaceutically acceptable salts, in pharmaceutically effective amounts. A method for treating acute lymphoblastic leukemia expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to a subject in need.
[0188] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of one or more anticancer agents selected from the group consisting of vincristine, dexamethasone, prednisone, doxorubicin, and daunorubicin, or a pharmaceutically acceptable salt thereof. A method for treating acute lymphoblastic leukemia expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to a subject in need.
[0189] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) One or more anticancer agents selected from the group consisting of methotrexate, 6-mercaptopurine (6-MP), vincristine, prednisone, and imatinib, or their pharmaceutically acceptable salts, in pharmaceutically effective amounts. A method for treating acute lymphoblastic leukemia expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to a subject in need.
[0190] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) A pharmaceutically effective amount of one or more anticancer agents selected from the group consisting of ibrutinib, acalabrutinib, idelalisib, and duvelisib, or a pharmaceutically acceptable salt thereof. A method for treating chronic lymphocytic leukemia expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to a subject in need.
[0191] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (b) a pharmaceutically effective amount of venetoclax or a pharmaceutically acceptable salt thereof A method for treating chronic lymphocytic leukemia expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to a subject in need.
[0192] (a) a pharmaceutically effective amount of the compound of formula (I) or a pharmaceutically acceptable salt thereof; and (c) One or more anticancer agents selected from the group consisting of rituximab, ofatumumab, and obinutuzumab, or their pharmaceutically acceptable salts, in pharmaceutically effective amounts. A method for treating chronic lymphocytic leukemia expressing the YB1 (YBX1) protein in a subject is also provided, which includes the step of administering the YB1 (YBX1) protein to a subject in need.
[0193] definition The terms "YB1" and "YBX1" refer to Y-box binding protein 1, also known as Y-box transcription factor or nuclease-sensitive element binding protein 1, which is the protein encoded by the YBX1 gene in humans.
[0194] Wavy lines in chemical structures TIFF2023552368000008.tif4128 shows the bonds to which the shown structure is attached to other chemical moieties or groups.
[0195] In this specification, "heterocycle" or "heterocyclic group" refers to a chemical ring comprising a carbon atom and at least one ring heteroatom selected from O, S, and N. The terms "heterocycle" and "heterocyclic formula" include groups having saturated rings, partially unsaturated rings, and aromatic rings (i.e., aromatic heterocycles). Examples of five-membered and six-membered heterocycles include, for example, non-limitingly, pyridyl, dihydropyridyl, tetrahydropyridyl (piperidyl), thiazolyl, tetrahydrothiophenyl, and sulfur-oxidized tetrahydrothiophenyl. This includes tetrahydrothiophenyl, pyrimidinil, furanil, thienyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, 4-piperidinil, pyrrolidinil, 2-pyrrolidonil, pyrrolinil, tetrahydrofuranil, triazinil, 6H-1,2,5-thiadiadinil, 2H,6H-1,5,2-dithiadinil, thienyl, thianthrenil, pyranil, 2H-pyrrolyl, isothiazolyl, isoxazolyl, pyrazinil, pyridadinil, imidazolidinil, imidazolinil, pyrazolidinil, pyrazolidinil, piperazinil, morpholinil, and oxazolidinil.
[0196] The term "alkyl" refers to linear or branched hydrocarbons. For example, alkyl groups may have 1 to 6 carbon atoms (i.e., C1-C6 alkyl), 1 to 4 carbon atoms (i.e., C1-C4 alkyl), or 1 to 3 carbon atoms (i.e., C1-C3 alkyl). Suitable examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl (-CH(CH3)2), 1-butyl (n-Bu, n-butyl, --CH2CH2CH2CH3), 2-methyl-1-propyl (i-Bu, i-butyl, --CH2CH(CH3)2), 2-butyl (s-Bu, s-butyl, --CH(CH3)CH2CH3), and 2-methyl-2-propyl (t-Bu, t-butyl, --C(CH3 )3), 1-Pentyl(n-Pentyl,--CH2CH2CH2CH2CH3), 2-Pentyl(--CH(CH3)CH2CH2CH3), 3-Pentyl(--CH(CH2CH3)2), 2-Methyl-2-butyl(-C(CH3)2CH2CH3), 3-Methyl-2-butyl(--CH(CH3)CH(CH3)2), 3-Methyl-1-butyl(--CH2CH2CH(CH3)2), 2-Methyl-1-butyl methyl(-CH2CH(CH3)CH2CH3), 1-hexyl(--CH2CH2CH2CH2CH2CH3), 2-hexyl(--CH(CH3)CH2CH2CH2CH3), 3-hexyl(-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl(-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl(-CH(CH3)CH(CH3)CH2CH3), 4-methyl This includes, but is not limited to, 2-pentyl(-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl(--C(CH3)(CH2CH3)2), 2-methyl-3-pentyl(-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl(--C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl(-CH(CH3)C(CH3)3), etc.
[0197] The term "alkoxy" refers to a group having the formula -O-alkyl, in which the alkyl group defined above is attached to the parent molecule via an oxygen atom. The alkyl portion of an alkoxy group may have 1 to 6 carbon atoms (i.e., C1-C6 alkoxy), 1 to 4 carbon atoms (i.e., C1-C4 alkoxy), or 1 to 3 carbon atoms (i.e., C1-C3 alkoxy). Suitable examples of alkoxy groups include, but are not limited to, methoxy (-O-CH3 or -OMe), ethoxy (-OCH2CH3 or -OEt), n-propoxy (-CH2-CH2-CH3), isopropoxy (-CH(CH3)2), n-butyl (-CH2-CH2-CH2-CH3), isobutoxy (-CH2-CH(CH3)2), sec-butoxy (-CH(CH3)CH2-CH3), t-butoxy (-OC(CH3)3 or -OtBu), etc.
[0198] The term "cycloalkyl" refers to saturated rings having 3 to 6 carbon atoms as a monocyclic ring, such as the cyclopropyl group, cyclobutyl group, cyclopentyl group, and cyclohexyl group.
[0199] The term “subject” refers to an animal, e.g., a mammal, that is or will be the subject of a treatment, observation, or experiment. The methods described herein may be useful in both the therapeutic and veterinary applications for humans. In some embodiments, the subject is a mammal; in some embodiments, the subject is a human; in some embodiments, the subject is selected from cats and dogs. “Subject requiring it” or “human requiring it” refers to a subject, e.g., a human, who may or is presumed to have a disease or condition that would benefit from a particular treatment, e.g., a treatment with a compound of formula (I), formula (II), or formula (III) described herein, or a pharmaceutically acceptable salt or cocrystal thereof. This includes subjects who are at risk of or may be determined to be susceptible to such a disease or condition, such that the treatment would prevent the development of the disease or condition.
[0200] In some embodiments, the "subject in need thereof" with respect to the methods of treatment herein is, for example, a patient from whom a tumor sample has been taken from a tumor biopsy and in which the presence of the YBX1 protein has been identified in the material taken, for example, through immunohistochemical techniques or Western blotting techniques known in the art.
[0201] The terms "effective amount", "therapeutically effective amount", or "pharmaceutically effective amount" refer to a sufficient amount to effect the treatment as defined hereinafter when administered to a subject (e.g., a mammal, e.g., a human) in need of such treatment. The therapeutically or pharmaceutically effective amount will vary depending on the subject and disease state, the weight and age of the subject, the severity of the disease state, the mode of administration, etc., and these can be readily determined by one of ordinary skill in the art. For example, the "effective amount", "therapeutically effective amount", or "pharmaceutically effective amount" of a compound of formula (I), formula (II), or formula (III), or a pharmaceutically acceptable salt or co-crystal thereof, is an amount sufficient to modulate the expression or activity of YXB1 and thereby treat a subject (e.g., a human) afflicted with an indication or to alleviate or mitigate existing symptoms of an indication. For example, the therapeutically or pharmaceutically effective amount can be an amount sufficient to reduce the symptoms of a disease or condition responsive to inhibition of YXB1 activity.
[0202] In some embodiments, an "effective amount" is an amount of the subject compound that is effective to inhibit YB-1 by about 20% (20% inhibition), at least about 30% (30% inhibition), at least about 40% (40% inhibition), at least about 50% (50% inhibition), at least about 60% (60% inhibition), at least about 70% (70% inhibition), at least about 80% (80% inhibition), or at least about 90% (90% inhibition) when administered one or more times to an individual, alone or in combination therapy, compared to the YB-1 activity in the individual in the absence of treatment with the compound or compared to the YB-1 activity in the individual before or after treatment with the compound.
[0203] In some embodiments, an "effective amount" is an amount of a compound of the subject matter that is effective to reduce the amount of tumor in a subject by about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% when administered one or more times to the subject in monotherapy or combination therapy, as compared to the amount of tumor in the subject in the absence of treatment with the compound, or as compared to the amount of tumor in the subject before or after treatment with the compound. As used herein, the term "amount of tumor" refers to the total amount of tumor tissue possessed by a subject having cancer. In some embodiments, an "effective amount" is an amount of a compound of the subject matter that is effective to decrease the dose of radiation therapy required to observe tumor shrinkage in a subject by about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least about 90% when administered one or more times to the subject in monotherapy or combination therapy, as compared to the dose of radiation therapy required to observe tumor shrinkage in the subject in the absence of treatment with the compound. In some embodiments, an "effective amount" of a compound is an amount that is effective to achieve a 1.5-log, 2-log, 2.5-log, 3-log, 3.5-log, 4-log, 4.5-log, or 5-log decrease in tumor size when administered one or more times to a subject having cancer.
[0204] In some embodiments, the compound of formula (I) or a pharmaceutically acceptable salt thereof may be administered at a daily dose of about 0.2 mg / kg to about 10 mg / kg. In other embodiments, it may be administered at a daily dose of about 0.2 mg / kg to about 5 mg / kg.
[0205] In some embodiments, the effective amount of the compound is approximately 50 ng / kg body weight to approximately 50 pg / kg body weight (for example, approximately 50 ng / kg body weight to approximately 40 pg / kg body weight, approximately 30 ng / kg body weight to approximately 20 pg / kg body weight, approximately 50 ng / kg body weight to approximately 10 pg / kg body weight, approximately 50 ng / kg body weight to approximately 1 pg / kg body weight, approximately 50 ng / kg body weight to approximately 800 ng / kg body weight, approximately 50 ng / kg body weight to approximately 700 ng / kg body weight, approximately 50 ng / kg body weight to approximately 600 ng / kg body weight, approximately 50 ng / kg body weight to approximately 500 ng / kg body weight, approximately 50 ng / kg body weight to approximately 400 ng / kg body weight, approximately 60 ng / kg body weight to approximately 400 ng / kg body weight). The amounts are in the range of approximately 70 ng / kg body weight to approximately 300 ng / kg body weight, approximately 60 ng / kg body weight to approximately 100 ng / kg body weight, approximately 65 ng / kg body weight to approximately 85 ng / kg body weight, approximately 70 ng / kg body weight to approximately 90 ng / kg body weight, approximately 200 ng / kg body weight to approximately 900 ng / kg body weight, approximately 200 ng / kg body weight to approximately 800 ng / kg body weight, approximately 200 ng / kg body weight to approximately 700 ng / kg body weight, approximately 200 ng / kg body weight to approximately 600 ng / kg body weight, approximately 200 ng / kg body weight to approximately 500 ng / kg body weight, approximately 200 ng / kg body weight to approximately 400 ng / kg body weight, or approximately 200 ng / kg body weight to approximately 300 ng / kg body weight.
[0206] In some embodiments, the effective amount of the compound is approximately 10 pg to approximately 100 mg, for example, 10 pg to approximately 50 pg, approximately 50 pg to approximately 150 pg, approximately 150 pg to approximately 250 pg, approximately 250 pg to approximately 500 pg, approximately 500 pg to approximately 750 pg, approximately 750 pg to approximately 1 ng, approximately 1 ng to approximately 10 ng, approximately 10 ng to approximately 50 ng, approximately 50 ng to approximately 150 ng, approximately 150 ng to approximately 250 ng, and approximately 250 mg. The amounts are in the range of g to approximately 500 ng, approximately 500 ng to approximately 750 ng, approximately 750 ng to approximately 1 pg, approximately 1 pg to approximately 10 pg, approximately 10 pg to approximately 50 pg, approximately 50 mg to approximately 150 gg, approximately 150 gg to approximately 250 gg, approximately 250 gg to approximately 500 gg, approximately 500 gg to approximately 750 gg, approximately 750 gg to approximately 1 g, approximately 1 mg to approximately 50 mg, approximately 1 mg to approximately 100 mg, or approximately 50 mg to approximately 100 mg. The amount may be a single dose or a total daily dose. The total daily dose may be in the range of 10 pg to 100 mg, or in the range of 100 mg to approximately 500 mg, or in the range of 500 mg to approximately 1000 mg.
[0207] In some embodiments, the compound is administered as a single dose. In other embodiments, it is administered multiple times. When administered multiple times over a period, the compound may be administered twice daily (qid), once daily (qd), every other day (qod), every three days, three times a week (tiw), or twice a week (biw) over that period. For example, the compound may be administered qid, qd, qod, tiw, or biw over a period ranging from one day to approximately two years or longer. For example, the compound may be administered at any of the above frequencies for a period of one week, two weeks, one month, two months, six months, one year, or two years or longer, depending on various factors.
[0208] Administration of an effective amount of the subject compound to an individual with cancer may result in one or more of the following: (1) a reduction in tumor burden; (2) a reduction in the dose of radiation therapy required to produce tumor reduction (e.g., due to sensitivity to radiation therapy); (3) a reduction in the spread of cancer from one cell to another in the individual; (4) a reduction in morbidity or mortality in clinical outcomes; (5) a reduction in the overall treatment duration when combined with other anticancer agents (e.g., due to sensitivity to other anticancer agents); and (6) an improvement in indicators of disease response (e.g., a reduction in one or more symptoms of cancer). Any of a variety of methods may be used to determine whether the treatment method is effective. For example, biological samples obtained from individuals treated by the subject method can be assayed.
[0209] The terms “inhibit” or “inhibit” refer to a reduction in the baseline activity of a biological activity or process, e.g., a significant reduction. “Inhibition of YB-1 activity” means a reduction in YB-1 activity compared to the activity of YB-1 in the absence of a compound of formula I or a pharmaceutically acceptable salt or cocrystal, as a direct or indirect response to the presence of such compound or pharmaceutically acceptable salt or cocrystal. The reduction in activity may result from a direct interaction between the compound and YB-1, or from an interaction between the compounds described herein and one or more other factors that instead affect YB-1 activity. For example, the presence of a compound can reduce YB-1 activity by directly binding to YB-1, by causing a reduction in YB-1 activity by other factors (directly or indirectly), or by reducing the amount of YB-1 present in a cell or organism (directly or indirectly). In some embodiments, inhibition of YB-1 activity may be compared to the same subject before treatment, or to other untreated subjects. The term "inhibitor" is understood to refer to a compound or drug that, when administered in a pharmaceutically or therapeutically effective dose to a person who needs it, provides the desired inhibitory activity.
[0210] The term "pharmaceutical composition" means a composition containing a pharmaceutically effective amount of one or more of the isotopic compounds described herein or their pharmaceutically acceptable salts, formulated on a pharmaceutically acceptable carrier, and possibly containing other excipients, manufactured or marketed under the authorization of a government regulatory authority as part of a therapeutic regimen for the treatment of a disease in a mammal. Pharmaceutical compositions may be formulated, for example, for oral administration in unit dosage forms (e.g., tablets, capsules, caplets, gel capsules, or syrups); for topical administration (e.g., as a cream, gel, lotion, or ointment); for intravenous administration (e.g., as a sterile solution without particulate stumps, in a solvent system suitable for intravenous use); or as any other formulation described herein. Conventional procedures and components for the selection and preparation of a suitable formulation are, for example, Remington: The Science and Practice of Pharmacy, 21 st This information is found in Ed., Gennaro, Ed., Lippencott Williams & Wilkins (2005) and in The United States Pharmacopeia: The National Formulary (USP 36 NF31), published in 2013.
[0211] As used herein, “pharmaceutically acceptable excipients” means, non-limitingly, any pharmaceutically acceptable media, including any carriers, solvents, dispersions, coatings, antimicrobial and antifungal agents, isotonic agents and absorption retarders, etc. The use of such media and agents for pharmaceutically active substances is well known in the art. Any conventional media or agent is intended to be used in the therapeutic composition, provided that it is not incompatible with the active ingredient. Supplementary active ingredients may be incorporated into the composition.
[0212] The term "pharmaceutically acceptable carrier" refers to any component in a pharmaceutical composition other than the disclosed pharmaceutically active compound or therapeutic compound or its pharmaceutically acceptable salts, which is non-toxic and non-inflammatory in the patient (e.g., a carrier capable of suspending or dissolving an active isotope compound). Excipients may include, for example, anti-adhesion agents, antioxidants, binders, coatings, compression aids, disintegrants, dyes (pigments), emollients, emulsifiers, bulking agents (diluents), film-forming agents or coatings, flavoring agents, fragrances, fluidizers (flow enhancers), lubricants, preservatives, printing inks, adsorbents, suspending agents or dispersants, sweeteners, or hydration water. Exemplary excipients include, but are not limited to, butylated hydroxytoluene (BHT), calcium carbonate, calcium phosphate (calcium hydrogen phosphate), calcium stearate, croscarmellose, cross-linked polyvinylpyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methylparaben, crystalline cellulose, polyethylene glycol, polyvinylpyrrolidone, povidone, pregelatinized starch, propylparaben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethylcellulose, sodium citrate, sodium starch glycolate, sorbitol, starch (corn), stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol.
[0213] The term "pharmaceutically acceptable salt" includes, for example, salts with inorganic acids and salts with organic acids. Examples of salts include hydrochlorides, phosphates, diphosphates, hydrobromides, sulfates, sulfinates, nitrates, malates, maleates, fumarates, tartrates, succinates, citrates, acetates, lactates, methanesulfons (mesylates), benzenesulfons (besylates), p-toluenesulfons (tosylates), 2-hydroxyethylsulfons, benzoates, salicylates, stearates, and alkanates (e.g., acetate, where n is 0-4 HOOC-(CH2)). n It may contain (-COOH). Furthermore, if the compounds described herein are obtained as acid addition salts, the free base can be obtained by basicizing the solution of the acidic salt. Conversely, if the product is a free base, the addition salt, specifically a pharmaceutically acceptable addition salt, can be prepared by dissolving the free base in a suitable organic solvent and treating the solution with an acid, following conventional procedures for preparing acid addition salts from base compounds. Those skilled in the art will recognize various synthetic methodologies that can be used to prepare non-toxic, pharmaceutically acceptable addition salts.
[0214] For compounds of formula I, pharmaceutically acceptable salts, pharmaceutically acceptable cocrystals, pharmaceutically acceptable esters, pharmaceutically acceptable solvates, hydrates, isomers (e.g., optical isomers, racemic compounds, or other mixtures thereof), tautomers, isotopes, polymorphs, and pharmaceutically acceptable prodrugs of such compounds are also described. For brevity, the above-mentioned list of forms cannot enumerate all compounds of formula (I), formula (Ia), formula (Ib), formula (Ic), formula (Id), formula (II), formula (III), SU056, etc., as described herein, but each is understood to be disclosed and included herein, even if only pharmaceutically acceptable salts are included in the description applied anywhere herein, for example, in relation to the compound, pharmaceutical composition, method of use / treatment, or other reference.
[0215] The term "crystalline form" and related terms, as used herein, refer to various crystalline modifications of a given substance, including, but not limited to, polymorphs, solvates, hydrates, cocrystals, and other molecular complexes, as well as salts, solvates of salts, hydrates of salts, other molecular complexes of salts, and their polymorphs. The crystalline forms of a substance can be obtained by a number of methods, as are known in the Art. Such methods include, but are not limited to, melt recrystallization, melt cooling, solvent recrystallization, recrystallization in confined spaces such as nanopores or capillaries, recrystallization on surfaces or templates such as polymers, recrystallization in the presence of additives such as cocrystal counter molecules, desolvation, dehydration, rapid evaporation, quenching, slow cooling, vapor diffusion, sublimation, grinding, and solvent droplet grinding.
[0216] As used herein with respect to cancer, the term “refractory” refers to cancer that does not respond to one or more treatments. In some embodiments, cancer does not respond to one or more chemotherapeutic agents. In other embodiments, cancer does not respond to radiotherapy. In other embodiments, refractory cancer does not respond to one or more chemotherapeutic agents and radiotherapy. Refractory cancer may be resistant at the initiation of such treatment, or it may become resistant throughout the course of one or more treatments. In the case of chemotherapy, refractory cancer is also called “chemotherapy-resistant cancer” or “chemo-resistant cancer.”
[0217] Androgen-independent prostate cancer, or hormone-refractory prostate cancer (AIPC), is prostate cancer that progresses after primary androgen deprivation therapy with either orchiectomy or a gonadotropin-releasing hormone (LHRH) agonist, followed by the addition of anti-androgens and subsequent tolerance. In some embodiments, hormone-refractory prostate cancer is defined as disease progression demonstrated by two or three consecutive elevations of prostate-specific antigen (PSA) levels obtained at intervals of more than two weeks, and / or findings from CT scans and / or bone scans, bone pain, or obstructive voiding symptoms. In some embodiments, PSA levels do not rise at diagnosis or throughout the course of the disease. In some embodiments, prostate cancer is advanced prostate cancer. In some embodiments, prostate cancer or metastatic prostate cancer is resistant to hormone-blocking therapy, such as abiraterone (ZYTIGA®), enzalutamide (XTANDI®), bicalutamide (CASODEX®), flutamide (DROGENIL®), or cyproterone acetate (CYPROSTAT®).
[0218] Cancer cells that are resistant to radiation therapy, whether intrinsically or acquired over time, are called "radiation-resistant cancer" or "radioresistant cancer." These terms are used to describe cancer cells that respond less to radiation therapy than non-resistant cancer cells.
[0219] All ranges disclosed and / or described in the claims herein include the described endpoints and are independently combinable. For example, the ranges “2 to 10” and “2-10” include the endpoints 2 and 10, as well as all intermediate values in the context of the units considered. For example, claims and atoms are numbered consecutively without fractions or decimals unless described in the context of average numbers, so “claims 2-10” or “C2-C 10References to "alkyl" include units 2, 3, 4, 5, 6, 7, 8, 9, and 10. On the other hand, situations of "pH of 5 to 9" or "temperature of 5°C to 9°C" include the integers 5, 6, 7, 8, and 9, as well as all fractional or decimal units in between, for example, 6.5 and 8.24.
[0220] "Significant" means a detectable change that is statistically significant (p < 0.05) in a standard parametric test for statistical significance, such as a Student's T-test.
[0221] The modifier "about" when used with respect to a quantity includes the stated value and has the meaning indicated by the context (e.g., including the degree of error associated with the measurement of a particular quantity). In some embodiments, the term "about" refers to plus or minus 10% of the indicated quantity. In some embodiments, the term "about" refers to plus or minus 5% of the indicated quantity.
[0222] The descriptions in this specification describe exemplary methods, parameters, etc. However, it should be recognized that such descriptions are not for limiting the scope of the present disclosure and are provided as explanations of exemplary embodiments.
Examples
[0223] Results Drug Design and Synthesis The inventors previously discovered 9-(3-fluorophenyl)-4-(2-hydroxyethyl)-6-methoxy-4,9-dihydrofl[3,4-b]quinoline-1(3H)-one, an effective azopodophyllotoxin-based small molecule that inhibits GBP1:PIM1 activity in vitro, and subsequently named it SU093 (Andreoli et al., J Med Chem, 57, 7916-32, 2014). This study revealed that SU093 is more active in cell lines that are more resistant to microtubule-targeting drugs, such as paclitaxel. Motivated by this study, the inventors designed an SU093 analog incorporating a fluorine (F) bioequivalent group to develop SU056, an optimized lead compound with improved inhibitory properties that can reduce OC disease progression and make cells more sensitive to OC chemotherapy.
[0224] The introduction and manipulation of bioequivalent groups offer several advantages in the drug design and development process, such as enhancing desired biological or physical properties, reducing toxicity, and even altering the metabolism of a given drug compound. Fluorine, considered the classical bioequivalent of hydrogen, has been extensively studied since the first fluorine-containing drug (9α-fluorocortisol) was approved in 1955 (Fried and Sabo, 1954). Over the years, several strategies for introducing fluorine into drug design have been developed. Incorporation of fluorine can affect the lipophilicity of a drug by introducing a strong dipole moment aligned near the carbonyl group, increasing the van der Waals radius of the active site compared to that of hydrogen (Gillis et al., 2015). Direct substitution of hydrogen or methyl (CH3) groups in known drugs can result in improved potency by altering the substrate's sensitivity to intracellular oxidative metabolism. This was observed in the case of paclitaxel, where the efficacy of the taxol derivative (3'-difluorovinyl taxoid) was enhanced by at least 1,000-fold by substituting two methyl groups with fluorine (Kuznetsova et al., 2012). Furthermore, this difluorotaxol derivative was resistant to metabolic modification by CYP 450 enzymes. Based on these observations, we modified the previously reported compound SU093 by introducing fluorine as a bioequivalent group into ring E, obtaining a novel AzP derivative SU056, synthesized using a multicomponent reaction similar to that of SU093 (Andreoli et al., 2014), as described in the supplementary information (Figure 1A).
[0225] AzP treatment inhibits the proliferation of ovarian cancer cells. AzP analogs were screened against a panel of ovarian cancer cell lines (OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, and SKOV-3), and further screened against cell lines HEK293, SH-SY5Y, and N27. The relationship between AzP dose and survival rates in human ovarian cancer cell lines and ID8 mouse ovarian cancer cell lines was examined. As shown in Figure 1B, SU056 showed better IC56 after 48 hours of treatment compared to SU093. 50 The values showed a decrease (up to 2x in OVCAR4, OVCAR5, and ID8 cells), and this trend was also reflected in the cloning assays shown in Figures 1C and 1D, where both inhibitors dose-dependently and significantly reduced OC colony formation in OVCAR-8 and ID8 cells. On the other hand, SU093 had a moderate effect on SKOV-3 at concentrations of 0.5 μM and 1 μM.
[0226] Etoposide is a natural podophyllotoxin and an approved chemotherapeutic agent used to treat many cancers. The main limitation of etoposide is the potential for neuropathy and neurotoxicity with long-term treatment. The cytotoxic effects of etoposide, SU093, and SU056 on the neuronal cell lines SH-SYSY and N27 were tested at a 10 μM dose for 48 hours, and their neurotoxicity profiles were compared. Cell viability assayed by MTT revealed that SU056 was significantly less cytotoxic than etoposide, exhibiting 49.54% (N27) and 28.51% (SH-SY5Y) low toxicity (Figure 1E). These results suggest that biological equivalence modification improved overall efficacy in inhibiting OC proliferation while reducing neurotoxic side effects.
[0227] AzP treatment causes cell cycle arrest, apoptosis, and inhibition of cell migration. To determine whether proliferation inhibition was the dominant factor driving the decrease in OC viability observed with AzP treatment, propidium iodide staining and annexin-FITC staining were used in conjunction with flow cytometry to measure the cell cycle distribution after treatment. The data showed significant dose-dependent arrest of OC cell lines in the sub-G1 and G1 phases of the cell cycle, and a corresponding decrease in the proportion of cells in the S or G2 / M phase (Figure 1F). SU056 showed greater cell cycle arrest than SU093. This trend was also reflected in the proportion of apoptotic cells in each treated culture, with AzP treatment significantly increasing apoptosis in each OC cell line studied at all doses (Figure 1G). Furthermore, in Boyden chamber assays for cell migration, SU093 inhibited cell migration by 40–46% (1 μM, P<0.05) in different OC cell lines. However, SU056 treatment was the most effective, inducing 78–87% inhibition (1 μM, P<0.05) in the cell line (Figure 1H). These data indicate that SU056 treatment mediates cell cycle arrest and significantly reduces proliferation and migration.
[0228] AzP inhibits tumor progression and metastasis in vivo. Based on these promising results, the inventors decided to test SU093 and SU056 in vivo. 2 × 10⁶ mice were given C57BL / 6 mice. 6 Individual ID-8 syngeneic ovarian cancer cells expressing firefly luciferase (luc+) were subcutaneously transplanted. The tumor size was 100 mm. 3After reaching a certain stage, daily intraperitoneal treatment with 20 mg / kg of SU093 and SU056 (medium control: 30% PEG-300 in physiological saline) was initiated. Tumor growth was monitored via bioluminescence imaging (IVIS). Treatment with SU093 and SU056 significantly delayed tumor progression compared to the medium control throughout the treatment period (Figures 2A and 2B). On day 42, the final assessment of tumor weight showed that SU056 treatment resulted in a twofold reduction in tumor weight, and SU093 reduced the tumor by 1.5 times (Figure 2C). This was without significant effects on blood chemistry indicators, such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), or alkaline phosphatase (Figure 2D), indicating that daily SU056 and SU093 is a well-tolerated treatment regimen.
[0229] Because a significant decrease in the migratory ability of OC cells treated with these two drugs had been previously observed (Figure 1H), we also measured the effect of drug treatment on ovarian cancer metastases. At the end of the above experiment, the lungs were fixed, metastatic lesions were counted under a surgical microscope, and then H&E staining was performed. Measurement of metastases in mice treated with SU056 showed a three-fold decrease in lung metastases, as assessed via histological scoring (Figures 2E and 2F). Based on these data and the excellent performance in all assays, SU056 was selected for further research.
[0230] Target identification: SU056 interacts with proteins associated with oncogenesis. The cellular thermal shift assay (CETSA) is based on the principle that protein-ligand interactions cause a shift in the thermal stability of proteins (Savitski et al., 2014). When a protein interacts with a ligand, its thermal stability increases, and this principle allows for the identification of protein targets to which small molecules or drug candidates associate. This assay was used to identify the protein targets of SU056. OVCAR8 cells were treated with SU056 (2.5 μM) for 1.5 hours, and the protein lysates were analyzed for thermal shift. The heatmap shows the thermal stability of 804 soluble proteins in the presence and absence of SU056, compared to 37°C (Figure 3A). In both cells treated with the medium control and cells treated with SU056, 77% of the proteins were identified, and 97% of these proteins met the criteria for fitting to the melting curve. The compression of thermal stability between DMSO-treated and SU056-treated proteomes suggests that SU056 treatment increases the overall stability of the cellular proteome (Figures 3A, 3B, and 3C). SU056 treatment significantly increased the thermal stability of six proteins out of 804 soluble proteins (p < 0.01 and RSQ > 0.7) (Figure 3D). These six proteins are YBX1 (YB-1), TMSB10, SUMO2, PSMB2, TMSB4X, and CALM3 (Figure 3D). The melting curves of these proteins, both with and without SU056, suggest that SU056 increases the thermal stability of YB-1, TMSB10, SUMO2, PSMB2, TMSB4X, and CALM3 by 5.92±0.86°C, 5.89±1.18°C, 5.4±1.08°C, 5.36±0.76°C, 4.43±1.31°C, and 4.03±1.07°C, respectively (Figures 3E and 3F). These results were further validated using Western blotting (WB) (Figure 8A). All six of these proteins have been previously reported to contribute to carcinogenesis.
[0231] SU056 treatment inhibits YB-1. Of the six identified targets, proteins exhibiting a thermal shift greater than 5° in the presence of SU056 were selected for further study of post-treatment protein expression. Western blot analysis of OVCAR8 cells treated with DMSO and SU056 (1 μM, 2.5 μM, and 5 μM) for 12 hours suggests that SU056 treatment inhibits YB-1, TMSB10, SUMO2, and PMSB2 proteins in a dose-dependent manner (Figure 4A). Given the strong inhibition of YB-1 expression by SU056, and considering the role of YB-1 in interactions with many oncogenic protein treatment resistance factors, YB-1 was selected for further validation. To study the in vivo effects of SU056 treatment, ID8 tumor xenograft samples were analyzed via immunohistochemistry (IHC). IHC of YB-1 and MDR1 expression in tumors treated with the medium and SU056 (20 mg / kg) suggests that SU056 strongly inhibits YB-1 expression and subsequently downregulates downstream MDR1 (Figure 4B). To identify the broader effects of SU056 on YB-1 and its downstream proteins / activities in different ovarian cancer cell lines, six different cell lines were selected and treated with SU056 (2.5 μM) for 12 hours. Cells were analyzed for YB-1 and CD44 expression, as well as multidrug resistance 1 (MDR1, ABC pump-mediated efflux). The results suggest that this treatment inhibits YB-1 expression by 28–56%, accompanied by a 36–70% decrease in CD44 expression and a 41–63% decrease in MDR expression (Figure 4C). These results suggest that SU056 broadly inhibits YB-1 in different OC cell lines, regardless of genetic background and cancer stage. SU056 50% YB-1 inhibitory concentration (IC) 50 To calculate the IC50 of OVCAR4, OVCAR8, and SKOV3, cell lines were treated with SU056 (0.01 μM, 0.1 μM, 1 μM, 10 μM) for 12 hours, and YB-1 expression was analyzed using YB-1 ELISA. 50The values were 5.6±0.36 μM, 3.2±0.19 μM, and 3.7±0.21 μM, respectively (Figure 4D). Finally, the chronokinetic and dose-dependent effects of SU056 on YB-1 expression were examined. OVCAR4, OVCAR8, and SKOV3 cells were treated with SU056 (1 μM, 2.5 μM, and 5 μM) for 3 hours, 6 hours, 12 hours, and 24 hours, and YB-1 expression was measured using YB-1 ELISA. The results suggest that SU056 treatment inhibits YB-1 in a time-dependent and dose-dependent manner (Figure 4E). 24-hour treatment with 5 μM completely (100%) inhibited YB-1 in all three OC cell types (Figure 4E). This result was further confirmed using OVCAR8 cells that stably express mCherry-tagged YB-1. Confocal imaging and fluorescence intensity measurements of YB-1 OVCAR8 cells also suggest that SU056 treatment inhibits YB-1 expression in a time-dependent and dose-dependent manner (Figures 8B and 8C). Overall, the results for YB-1 expression and its downstream factors (Figure 4) suggest that SU056 is a potent inhibitor of the YB-1 protein and its activity.
[0232] SU056 biophysically binds to YB-1, and its cellular activity is YB-1 dependent. Previously, we reported that SU093 interacts with GBP1 and inhibits GBP1:PIM1 interaction (Andreoli et al., 2014). SU056 is a second-generation small molecule derivative of SU093, and to determine whether it has the same molecular target as SU093, we performed a pull-down assay using biotinylated SU056 (Figure 5A). Pull-down assays from cells and protein lysates treated with biotinylated SU056 showed that SU056 physically interacts with YB-1 but not with GBP1 (Figure 5B). This result suggests that SU093 and SU056 have structural similarities but very different targets. To further support this, we performed surface plasma resonance (SPR) screening to measure orthogonal biophysical coupling between YB-1 and SU093 or SU056. His-tagged YB-1 protein was immobilized on GE NTA chips, and binding to SU093 and SU056 at different concentrations (1–100 μM) was tested (Figure 5CD). SPR results also support the finding that SU056:YB-1 has a stronger biophysical interaction (Figure 5D) compared to SU093 (Figure 5C). To check the dependence of SU056 activity on YB-1 expression, OVCAR8 cells transfected by YB-1 knockdown using lentiviral shRNA vector transduction were also tested. Using two different shRNA sequences (YBX1-shRNA1 and YBX1-shRNA2), both inhibited YB-1 expression by 80–90% compared to cells transduced by a scrambled control (SC) (Figure 5E). Cloning assays were performed using these three cell lines, both with and without SU056 (1 μM). The results suggest that YB-1 knockdown cells are more resistant to SU056 treatment compared to SC cells (Figure 5F). Furthermore, IC 50 To calculate the values, a cell viability assay was also performed using knockdown cells. IC of SU056 against SC cells. 50The IC50 was 3.54 μM (±0.21), while the IC50 for YBX1-shRNA1 and YBX1-shRNA2 were 15.84 (±0.13) and 19.15 (±0.34), respectively (Figure 5G). YB-1 knockdown resulted in approximately 5 times higher IC50 compared to SC. 50 The values were increased. These results indicate that the effect of SU056 depends on the cellular expression of YB-1.
[0233] SU056 modulates YB-1-related proteins and pathways. CETSA results indicate that SU056 physically interacts with YB-1 and inhibits YB-1 and its activity. To study the effect of SU056 on the stability of the YB-1 protein, a cycloheximide chase (CHX) assay was used. Cycloheximide is a protein translation inhibitor and is used as a molecular biology tool to determine the half-life of a protein. OVCAR8 cells were treated with CHX and DMSO or SU056 (2.5 μM), and after collecting protein lysates at different time points (0 min, 30 min, 60 min, 120 min, 180 min), YB-1 immunoblotting was performed. The results suggest that SU056 treatment leads to proteasomal degradation, shortening the half-life of YB-1 from approximately 130 minutes to approximately 40 minutes (Figure 6A). YB-1 is involved in the transcription and translation of many oncogenic proteins, including CD44, ABCB1 / MDR1, c-Myc, and Bcl-2. Immunoblotting of whole cell lysates from SKOV3 and OVCAR8 cells treated with DMSO or SU056 (2.5 μM, 12 hours) showed that SU056 treatment inhibited the YB-1 protein (Figure 6B). Subsequently, the expression of CDK2, CDC25A, MDR1, CD44, c-Myc, and Bcl-2 decreased, while the expression of the pro-apoptotic protein Bax increased (Figure 6B). To evaluate the proteomic changes induced by SU056, proteomic profiling was performed on OVCAR8 cells treated with DMSO and SU056 (2.5 μM, 12 hours).GSEA KEGG analysis of the obtained proteomics data suggests that SU056 treatment significantly induces the following pathways: apoptosis (ES=0.792, p-0.01), RNA degradation (ES=0.783, p-0.03), alanine, aspartic acid, and glutamic acid metabolism (p-0.02), arginine and proline metabolism (p-0.04), FcεRI signaling pathway (p-0.01), T cell receptor signaling pathway (p-0.02), natural killer cell-mediated cytotoxicity (p-0.03), epithelial cell signaling in Helicobacter pylori infection (p-0.04), and FcγR-mediated phagocytosis (p-0.05) (Figures 6C-D, Table 1). On the other hand, SU056 treatment also inhibits the spliceosome pathway (ES = -0.413, p-value -0.02) (Figure 6CE, Table 1). YB-1 protects and stabilizes mRNA via 5' end capping (Evdokimova et al., 2001) and enhances exon splicing (e.g., alternative splicing of CD44) (Stickeler et al., 2001). YB-1 inhibition via SU056 treatment inhibits the spliceosome pathway and induces RNA degradation and apoptosis. These results suggest that SU056 primarily targets YB-1, and then inhibits various YB-1-related proteins and pathways involved in cancer progression and TR.
[0234] YB-1 inhibition via SU056 treatment makes OC sensitive to paclitaxel. YB-1 is involved in the emergence of drug resistance to cisplatin and taxanes (Kang et al., 2013, Mo et al., 2016). Therefore, we investigated whether SU056 modulates YB-1 and thus synergistically acts with chemotherapy such as paclitaxel. To measure this, we conducted dose-dependent combination studies of SU056 and paclitaxel. Using the MTT assay, we found that SU056 treatment significantly enhanced the cytotoxic effect of paclitaxel at doses of 0.1 nM, 0.5 nM, and 1 nM (Figure S2, 7A). Treatment with 0.5 μM or 1.0 μM SU056 significantly reduced cell viability in both OC cell lines, OVCAR8 and SKOV-3. Combination index (CI) calculations using the Chou-Talalay method yielded CI values of less than 1 for the SU056 and paclitaxel combination. A CI of less than 1 suggests a significant synergistic effect between SU056 and the growth inhibitory effect of paclitaxel (Figure 7A). The ABCB1 / MDR1 drug efflux pump is also known to play an important downstream role, along with YB-1, in increased taxol efflux and subsequent TR in cancer. To evaluate whether SU056 affects drug efflux, Alexa Fluor-488-tagged paclitaxel was used to measure taxol efflux in vitro. The results suggested that co-treatment with SU056 significantly inhibited paclitaxel efflux compared to cells treated with paclitaxel alone (Figure 7B). Efflux is primarily driven by ATP-binding cassette transporters (ABC pumps) present on the cell surface (Genovese et al., 2017). Expression of MDR1 and YB-1 in OVCAR8 cells treated with a combination of the medium, SU056, and paclitaxel was examined via Western blotting. Immunoblotting results show that paclitaxel treatment alone is sufficient to upregulate the expression of YB-1 and MDR1, and that this is then reversed by the combination treatment of SU056 and paclitaxel (Figure 7C).These results strongly suggest that SU056 acts synergistically with the efficacy of paclitaxel.
[0235] 3D spheroids are an alternative tumor model that closely mimics the TR phenotype through increased drug efflux. OVCAR8 and SKOV3 cells were cultured in ultra-low adhesion plates with growth factor synthesis medium, either in the presence or absence of paclitaxel and SU056. The results show that the combination of SU056 and paclitaxel significantly inhibits spheroid formation by OC cells (Figures 7D and 7E). Cells treated with the combination formed 78% (OVACR8) and 83% (SKOV3) fewer spheroids than cells treated with the medium alone (Figure 7E).
[0236] In in vivo pharmacokinetic studies, an injection of 20 mg / kg SU056 was observed in approximately 45 minutes. 1 / 2 This resulted in a peak serum concentration of 28.19 μg / mL. Next, as described above, the synergistic effect of in vivo co-treatment with paclitaxel and SU056 was tested in NOD-SCID mice transplanted with OVCAR8 OC tumors. Mice were administered SU056 daily (10 mg / kg) and paclitaxel weekly (5 mg / kg) intraperitoneally. Both paclitaxel and SU056 treatments independently showed a significant reduction in OC tumor growth. However, the combination of paclitaxel and SU056 showed a much greater reduction in OC tumor growth and effectively stabilized disease progression during the treatment period (Figures 7F and 7G). The drug combination showed a sustained inhibitory effect on tumor growth until the end of the experiment (Figure 7H). Using Ki-67 staining, the proliferation index was also measured in the resected tumors (Figure 7I). This showed that both SU056 and paclitaxel exerted independent antiproliferative effects, and when combined, they acted synergistically, producing a greater therapeutic effect. This is likely due to reduced paclitaxel efflux from OVCAR8 cells in the presence of SU056.
[0237] Consideration Ovarian cancer (OC) is the fifth most common cancer in women, and the overall 5-year survival rate in the United States (USA) is only 47.6%. Surgical resection and chemotherapy are the primary treatments for OC, but there are limitations, such as the difficulty of surgery due to the abdominal spread of metastatic OC and the high 2-year recurrence rate of 80-90% after chemotherapy with taxanes or platinum (Jayson et al., 2014, Agarwal and Kaye, 2003). Paclitaxel provides some effect, but recurrent disease is frequently triglyceride (TR), and tumor cells evade or overcome the molecular mechanisms of cytotoxicity despite ongoing treatment (Singh and Settleman, 2010, Blagosklonny and Fojo, 1999, Horwitz et al., 1986). A study by Sood's group investigating the mechanism of transduction (TR) in taxane-resistant occlusion (OC) revealed that YB-1 was significantly upregulated in treated OC patients, and that patients with high YB-1 expression had significantly shorter overall survival (Kang et al., 2013). Here, we report a novel, potent, and highly effective YB-1 inhibitor, a fluorine-based derivative of podophyllotoxin, which can suppress disease progression and act synergistically with chemotherapy.
[0238] Overexpression of βIII-tubulin is a prominent sign of paclitaxel-TR, and GBP1:PIM1 interaction can help activate its function (De Donato et al., 2012, Mariani et al., 2011). Our group previously reported small molecule podophyllotoxin (SU093) as an inhibitor of GBP1:PIM1 interaction that can overcome taxane resistance in vitro (Andreoli et al., 2014). To improve the potency of SU093, we constructed a second-generation compound library through structural information-based strategies and biological equivalent substitution strategies. Screening of this library revealed that the fluorine-based derivative SU056 has significantly improved potency and safety through a different mechanism of action. Screening of SU056 for cytotoxic effects showed improved efficacy compared to SU093. Both SU093 and SU056 induced G1 cell cycle arrest, increased apoptotic cell death, and inhibited cell migration. Both compounds also inhibited tumor progression and metastasis in an ID8 xenograft model. Neither compound caused hepatotoxicity during treatment. In each assay, SU056 proved potent compared to SU093 or other AzP derivatives and was therefore selected for further study.
[0239] To identify the targets of SU056, a cellular thermal shift assay (CETSA) was used, revealing that the compound interacts with YB-1, TMSB10, SUMO2, PSMB2, TMSB4X, and CALM3. Target identification suggests that SU056 inhibits proteins that play an oncogenic role in ovarian cancer and / or other cancers. SU056 treatment was found to reduce YB-1 expression in a dose- and time-dependent manner in various OC cell lines. Our experiments validated that SU056 treatment strongly interacts with YB-1 and inhibits related downstream proteins and pathways. SU056 arrests OC cells in the G1 phase and also inhibits the major drivers of the G1 / S phase (CDK2 and CDC25A). On the other hand, YB-1 plays a role in the phosphorylation and activation of CDC25A to drive G1 / S phase progression (Zhao et al., 2016), and knockdown of YB-1 results in G0 / G1 phase arrest (Harada et al., 2014). CD44, c-Myc, and MDR1 are the most prominent oncogenic downstream proteins regulated by YB-1, and SU056 treatment significantly inhibits their expression. YB-1 is an mRNA-binding protein involved in nuclear protein filament formation in the cytoplasm (Kretov et al., 2019). Along with YB-2 and YB-3, YB-1 binds to the cold shock domain of single-stranded RNA / DNA (Graumann and Marahiel, 1998). It is involved in the shuttle transport of nucleic acids in both the cytoplasm and nucleus (Matsumoto and Wolffe, 1998). In the cytoplasm, it regulates RNA stability, translational activity, and alternative splicing (Chansky et al., 2001). In the nucleus, it binds to specific promoter sequences to regulate the transcription of oncogenic proteins, e.g., MDR1 (Bargou et al., 1997). SU056-mediated YB-1 inhibition significantly upregulates the RNA degradation pathway while inhibiting the spliceosome pathway; this result is consistent with the literature on YB-1 function.In summary, the SU056:YB-1 interaction inhibits YB-1 activity in various OC cell lines via proteasomal degradation, thereby inhibiting various downstream factors involved in tumor progression and triglyceride (TR). These results confirm the YB-1 inhibitory activity of SU056 as a novel drug candidate.
[0240] Furthermore, when the effect of SU056 in combination with paclitaxel was investigated, it was found that a lower dose of SU056, 10 mg / kg, enhanced the cytotoxic effect of paclitaxel treatment. This effect may be because co-treatment with SU056 reduces the rate of paclitaxel efflux in OC cells. Drug efflux by cancer cells is one of the important mechanisms in the development of TR (Li and Nikaido, 2009; Gottesman and Pastan, 2015). Efflux is mainly driven by ATP-binding cassette (ABC) transporters present on the cell surface. This superfamily includes ABCB1, P-glycoprotein, ABCC1 (MRP1), and ABCG2 (BCRP / MXR), also known as multidrug resistance 1 (MDR1) (Fletcher et al., 2010). Paclitaxel is a substrate of ABCB1, and paclitaxel treatment upregulates its expression in various cancer types (Gottesman and Pastan, 1993). ABC transporters are characteristic of both cancer progression and TR and are considered a potential therapeutic target. While chemotherapeutic inhibitors of ABCB1 have been developed, first-, second-, and third-generation compounds have failed in clinical trials to date. First-generation compounds have toxicity issues, and second-generation compounds, such as Valspodar, did not demonstrate treatment benefit in combination with paclitaxel or carboplatin in patients with ovarian or peritoneal cancer (Lhomme et al., 2008). Third-generation inhibitors, such as Zosuquidar, also showed no benefit (Ruff et al., 2009), and inhibition of MDR1 and TR phenotypes remains an unaddressed clinical goal. In studies investigating the effects of paclitaxel, SU056, and combinations thereof on the expression of MDR1 and YB-1, paclitaxel treatment was found to upregulate the expression of both YB-1 and MDR1, while SU056, alone or in combination with paclitaxel, significantly reduced the expression of both MDR1 and YB-1.This is supported by paclitaxel efflux data showing that SU056 treatment inhibits MDR1, resulting in higher intracellular concentrations and activity of paclitaxel.
[0241] Tumor spheroids, a common 3D cell culture model, have been used to investigate changes in stem cell characteristics, efflux, and MDR1 expression after treatment (Wartenberg et al., 2005, Wartenberg et al., 1998, Chen et al., 2017). In this study, treatment of OC cells with a combination of paclitaxel and SU056 significantly inhibited spheroid formation ability, thus indicating a reduction in tumorigenic potential. Previous transcriptome analyses of taxane-resistant ovarian cancer cell lines have revealed elevated levels of both YB-1 and MDR1 (Sun et al., 2015, Kuwano et al., 2004, Shiota et al., 2014, Wu et al., 2007). YB-1 is involved in the transcriptional regulation of ABC transporters and epithelial-mesenchymal transition-related proteins involved in disease progression and TR (Lim et al., 2018, Wu et al., 2014, Evdokimova et al., 2009). Co-treatment with SU056 and paclitaxel was sufficient to halt tumor progression in an OVCAR8 xenograft model. This further suggests that SU056 and its analogues described herein offer a promising strategy for OC, rescuing treatment efficacy and increasing patient survival.
[0242] In summary, biological equivalent substitution was a highly effective chemical strategy to optimize SU093 for improved efficacy and reduced toxicity, leading to the development of SU056 and its corresponding analogues described herein. These AzP derivatives are the first reported inhibitors for YB-1 and ultimately reduce cell proliferation and migration in vitro and in vivo, while making OC cells sensitive to the cytotoxic effects of paclitaxel. Additional studies to characterize the effects of SU056 treatment on different animal models, other cancer types, and the immunomicroenvironment will provide further insights into the potential of SU056 and its analogues to combat treatment resistance in clinical settings.
[0243] material and method Compound Synthesis: As previously reported, the AzP derivative SU093 was synthesized and characterized (Andreoli et al., 2014). SU056 and biotinylated SU056 were synthesized according to the following protocol.
[0244] Synthesis of SU056 TIFF2023552368000009.tif46143
[0245] A solution of arylamino alcohol SI (Kumar et al., 2010) (1 mmol), 3-fluorobenzaldehyde (SIII) (1.2 mmol), L-proline (0.1 mmol, 10 mol%), and tetronic acid (SII) (1.2 mmol) was prepared in anhydrous ethanol (4 mL), and the reaction mixture was refluxed for 3-4 hours. When the amino alcohol component was consumed and a fluorescent spot appeared via TLC (9:1 50% siRNA / Hex:MeCN), a silica gel slurry was prepared and purified by flash chromatography to obtain SU056 as a solid (0.203 Gm 50%). TIFF2023552368000010.tif52165
[0246] Synthesis of biotinylated SU056 TIFF2023552368000011.tif65128
[0247] 2-(9-(3-fluorophenyl)-8-oxo-6,9-dihydro-[1,3]dioxolo[4,5-g]fl[3,4-b]quinoline-5(8H)-yl)ethyl 3-((2-(5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazole-4-yl)pentanamide)ethyl)disulfaneyl)propanoate: 9-(3 in anhydrous DMF (10.0 mL) under a nitrogen atmosphere A solution of -fluorophenyl)-5-(2-hydroxyethyl)-6,9-dihydro-[1,3]dioxolo[4,5-g]flou[3,4-b]quinoline-8(5H)-one (40.0 mg, 0.108 mmol) was treated with 3-[2-N-(biothinyl)aminoethyldithio]propanoic acid (44.0 mg, 0.108 mmol), EDC.HCl (31.1 mg, 0.162 mmol), and DMAP (19.8 mg, 0.162 mmol). The reaction mixture was stirred at room temperature for 18 hours and then diluted with water (approximately 10 mL). The mixture was then extracted with ethyl acetate (2 × 25 mL). The combined organic phase was washed with water and then with a salt solution. The organic phase was dried over Na₂SO₄, filtered, and evaporated to dryness. The crude product was purified by CombiFlash chromatography on silica gel using 0-10% methanol in dichloromethane as the eluent. The combined pure fraction was evaporated to dryness, and the desired product was obtained as an off-white solid (15.0 mg, 19%). TIFF2023552368000012.tif61166
[0248] General synthesis: The compounds described herein may be prepared by methods known in the art, for example, those described in the paper, Synthesis of Novel Functionalized 4-Aza-2,3-didehydropodophyllotoxin Derivatives with Potential Antitumor Activity, Kumar et al., J. Heterocyclic Chem., 47(6), 1275-1282, November 2010.
[0249] TIFF2023552368000013.tif28145
[0250] 2-(benzo[d][1,3]dioxol-5-ylamino)ethane-1-ol can be prepared by gradually adding 2-chloroethyl carbonochloride to anhydrous dichloromethane and pyridine containing benzo[d][1,3]dioxol-5-amine. The mixture is stirred at room temperature for 2.5 hours, washed with water, dried over anhydrous magnesium sulfate, concentrated under vacuum, and then washed, concentrated, and dried again.
[0251] TIFF2023552368000014.tif99128
[0252] A benzaldehyde compound having the desired substitution is reacted with tetronic acid in ethanol and refluxed for 30-90 minutes to form a comparablely substituted (Z)-3-benzylidenefuran-2,4(3H,5H)-dione, which is then reacted with 2-(benzo[d][1,3]dioxol-5-ylamino)ethane-1-ol to finally obtain the substituted 5-(2-hydroxyethyl)-9-phenyl-6,9-dihydro-[1,3]dioxol[4,5-g]flo[3,4-b]quinoline-8(5H)-one of interest. The synthesis of the corresponding chloro analog, 9-(3-chlorophenyl)-5-(2-hydroxyethyl)-6,9-dihydro-[1,3]dioxolo[4,5-g]flo[3,4-b]quinoline-8(5H)-one, can also be seen in U.S. Patent Application Publication No. 2017 / 0342086 (Kumar).
[0253] method: Pharmacokinetic Studies: Plasma concentrations of SU056 were determined by quantified mass analysis using an Agilent 6490 iFunnel triple quadrupole (QQQ) mass spectrometer equipped with an Agilent 1290 infinity II UHPLC. An analytical C18 column, ZORBAX C18 (Eclipse Plus, 2.1 × 50 mm, particle size 1.8 μm), was used. The mobile phase consisted of 60% water buffered with 0.1% formic acid and 4 mM ammonium formate, and 40% acetonitrile buffered with 0.1% formic acid. The mobile phase flow rate was set to 0.4 mL / min, and the column temperature was adjusted to 30°C. The electrospray ionization source was operated in positive ion mode. Mass spectrometer parameters were optimized as follows: source temperature 550°C, nebulizer gas (nitrogen) 20 psi, ion spray (IS) voltage 5000 V, and collision energy 21 V. Multiple reaction monitoring (MRM) was used to detect SU056 and the internal standard (IS), a similar analog of SU056, 4-(2-hydroxyethyl)-6-methoxy-9-phenyl-4,9-dihydrofl[3,4-b]quinoline-1(3H)-one. The precursor ion [M+H]+ and product ion for SU056 were monitored at m / z 370.0 and m / z 274.2, respectively. The precursor ion [M+H]+ and product ion for IS were monitored at m / z 338.1 and m / z 260, respectively. A calibration curve was constructed using known concentrations of SU056 and IS, and this curve was used to calculate unknown concentrations of SU056 in plasma at different time points. At time point zero, SU056 was intraperitoneally injected into each mouse at a dose of 20 mg / kg. Blood was collected retroorbitally at 5, 15, 30, 60, 120, 240, and 360 minutes after injection. Plasma was separated via centrifugation at 7,000 RPM for 10 minutes. 5 μL of plasma was taken from each sample and mixed with 10 μL of IS solution and 990 μL of MS-grade acetonitrile, then vortexed for 30 seconds and incubated at RT for 5 minutes.The mixture was centrifuged at 11,000 RPM at 4°C for 15 minutes, the supernatant was collected, and further purified by recentrifugation. Each protein-free plasma fraction (n=3) was used to determine the concentration of SU056 using the aforementioned HPLC / MS MRM method.
[0254] (Table 1) The most significant (mean p<0.05) process found to be enriched after 12 hours of treatment with SU056 according to GSEA, using the KEGG pathway database. Proteins shown in bold were enriched in each pathway. TIFF2023552368000015.tif146170
[0255] Cell lines: Human ovarian cancer (OC) cell lines, OVCAR3, OVCAR4, OVCAR5, OVCAR8, and SKOV-3 were obtained from the NCI Cell Line Repository (DTP). SH-SY5Y and N27 cell lines were obtained from Dr. Manish Chamoli (Buck Institute, CA, USA). ID8 cells and luciferase-tagged ID8 cells were obtained from Dr. Erinn Rankin (Stanford University, CA, USA). Scrambled control (SC), YBX1 knockdown (1&2), and mCherry-YBX1 OVCAR8 cell lines were generated using lentivirus-based transduction, selected using puromycin resistance, and then cell sorting. All OVCAR cells were maintained in RPMI-1640 (Corning, USA; #10-040-CV) supplemented with 10% FBS (Corning, USA; #35-015-CV) and 1% antibiotic-antifungal solution (Gibco, USA; #15240062). SKOV3 and ID8 cells were maintained in DMEM medium (Corning, USA; #10-013-CV) supplemented with 10% FBS and 1% antibiotic-antifungal solution. All cells were maintained at 37°C with 5% CO2. SH-SY5Y and N27 cells were maintained in DMEM / F12 medium (Hyclone, #SH30525.01) supplemented with 10% FBS and 1% antibiotic-antifungal solution. All cells were maintained at 37°C with 5% CO2. OVCAR8 cells were tagged with luciferase using the lentiviral vector-based plasmid pLenti PGK blast V5-LUC(w528-1) (donated by Eric Campeau & Paul Kaufman, Addgene#19166) and selected using blastosigin. Luciferase-tagged cells were maintained as described above.
[0256] Cell viability assay: Cell viability was assessed using a standard MTT assay protocol. Briefly, 5,000 cells were seeded into each well of a 96-well plate (Corning-Costar, #3598) and allowed to adhere for 24 hours. Cells were treated with the respective concentrations of compounds at each time point. Stock solutions of each compound were prepared in DMSO. The DMSO concentration was kept constant, below 0.1%. After each incubation, 50 μL of 0.5 mg / ml MTT solution prepared in 1×PBS was added to each well, and then incubated at 37°C in 5% CO2 for 1 hour. The MTT solution and medium were then removed, and the MTT formazan crystals were dissolved in 100 μL of DMSO per well. To quantify MTT crystallization, the absorbance at 570 nm for each well was recorded using a multimode plate reader. Each absorbance value was normalized to a control and converted to percentage cell viability.
[0257] Cloning assay: 300 suspended OC cells were seeded into each well of a 12-well plate (Corning-Costar, #3598) and incubated for 24 hours for adhesion. After 24 hours, the medium was replaced with medium containing the respective concentrations of the test compound, and incubated for 5–8 days until visible colonies appeared in the medium-treated wells. The cells were then washed, fixed with 2% paraformaldehyde, washed again, and stained with 0.5% crystal violet for 1 hour. The cells were destained using DI water and dried. Colonies were counted under a 100x microscope.
[0258] Cell cycle analysis: 30,000 OC cells were seeded in each well of a 12-well plate and incubated for 24 hours. Cells were treated with test compounds at their respective concentrations for 6 hours. Both live and dead cells were collected via trypsin treatment, and the cell pellet was fixed with 70% ethanol. Fixed cells were stained with a propidium iodide (PI) cocktail (80 μg / mL RNase A and 50 μg / mL PI in saponin-EDTA solution) and incubated overnight at 4°C. Each sample was analyzed using a Guava easyCyte flow cytometer (Millipore, Burlington, MA). The percentage of cells for each cell cycle was calculated using FlowJo software.
[0259] Apoptosis cell death assay: Cells were seeded and processed in the same manner as in the cell cycle analysis assay described above. Processed cells were incubated for 24 hours, and both live and dead cells were collected. Cells were stained with annexin V and PI using the FITC Annexin V Apoptosis Detection Kit (BD Pharmingen, San Jose, CA) according to the manufacturer's protocol. A Guava easyCyte flow cytometer was used to analyze the stained cells.
[0260] Cell migration assay: 1 × 10 540,000 cells were seeded in a 60 mm cell culture dish (Corning-Falcon, #353002) and incubated for 24 hours. Cells were treated with each compound at their respective concentrations for 12 hours. Cells were trypsinized and collected in conical tubes for each plate. The cell pellet was resuspended and viable cells were counted using a hemocytometer and trypan blue staining. 40,000 viable cells were then seeded in 0.2% FBS medium in the upper chamber of an 8 micron transwell (Corning-Falcon, #353097). The lower chamber contained 10% FBS complete medium. Cells were incubated at 37°C in 5% CO2 for 16 hours. Each transwell was washed to remove unmigrating cells and fixed using 75% ethanol. Fixed transwells were stained with 0.5% crystal violet for 1 hour. Destained transwell membranes were cut and mounted on slides using DPX mounting medium. The migrating cells were counted under a microscope at 100x magnification.
[0261] Cellular Thermal Shift Assay (CETSA): The assay was performed as previously described (Savitski et al., 2014). Briefly, OVCAR8 cells were treated with a medium (DMSO) or SU056 (2.5 μM) for 1.5 hours at 70–80% confluence. Cells were collected and washed twice with 1 × PBS. Cells were pelleted and resuspended in PBS. 1 × 10 6Ten different PCR tubes containing cells / tubes (in 100 μL PBS) were prepared for both groups. Using a thermal cycler (Biorad, CA, USA), the tubes were exposed to their respective temperatures (37°C, 41°C, 44°C, 47°C, 50°C, 53°C, 56°C, 59°C, 63°C, 67°C) for 3 minutes, followed by incubation at room temperature for 2 minutes. Each tube was rapidly frozen in liquid nitrogen. Cells were lysed using a freeze / thaw cycle, and soluble and insoluble fractions were separated by centrifugation at 14000 RPM at 4°C for 30 minutes. Equal volumes of the soluble fraction for each temperature from both groups were labeled with Tandem Mass Tag (TMT) using the manufacturer's protocol (TMT10plex® Isobaric Labeling Reagent Set, #90110, Thermo Fisher Scientific, Waltham, MA). TMT-labeled samples were analyzed using LC-MS / MS in three replicates, as previously described by our group (Going et al., 2018).
[0262] CETSA protein quantification, normalization, curve fitting, slope and melting point estimation, and statistical analysis: For both samples treated with the medium and samples treated with SU056, proteins were quantified from individual peptide spectra using a sum-based bootstrap algorithm with the corresponding TMT reporter ion intensities, after correcting for isotopic impurities using MaxQuant (Cox and Mann, 2008). For each sample, the lowest temperature was used as a reference to calculate the log2 ratio of the soluble fraction signals at each temperature, and each signal was compared to the highest temperature to estimate the percentage of signal lost in the soluble fraction. Using the same principle as previously described (Savitski et al., 2014), a curve fitting model to an S-shaped curve by the Boltzmann equation was used to describe the statistical behavior in a non-equilibrium thermodynamic system, such as a denaturation curve. To this end, the Boltzmann equation was solved by minimizing the difference in the sum of squares between the initial curve and the Boltzmann-fitted curve using a brute-force algorithm in R, in order to calculate the slope of the melting curve and the half-value and the temperature at which half of the protein denatured. Differences in melting points between fitted curves with a correlation greater than 0.75 and a p-value less than 0.01 were considered to be specific drug interaction agents.
[0263] Immunoblotting: After 70% confluence of OC cells seeded in 100 mm cell cultures was achieved, the dishes were treated with SU056 at respective concentrations for the respective times. At the end of the treatment, the cells were collected and lysed using M-PER® lysis solution (Thermo Scientific, #78503) supplemented with a Halt protease and phosphatase inhibitor cocktail (Thermo Scientific, #78440). Equal volumes (40-60 μg) of protein were separated using 8% / 10% / 12% SDS-PAGE gel electrophoresis. The proteins were then transferred to PVDF membranes (BioRad, #162-01277). The blocked membranes were incubated overnight at 4°C with gentle shaking, together with the respective primary antibody solutions prepared in 5% skim milk TPBS. The membranes explored with the primary antibody were washed and explored with the respective secondary antibody conjugated with HRP. Proteins were detected using Immobilon® Crescendo Western HRP substrate (Millipore, Germany) and visualized using the IVIS Lumina imaging system (Perkin Elmer, Waltham, MA).The following primary and secondary antibodies were used: YB-1 (Cell signaling technology (CST), #8475;1:2000), TMSB10 (R&D Systems, #AF6429;1:2000), SUMO2 / 3 (CST, #4971;1:1000), PSMB2 (Bethyl Laboratories, #A303817AT;1:1000), MDR1(CST, #13978;1:2000), CD44(CST, #37259;1:1000) ), c-Myc (Novusbio, #NB600-302SS;1:2000), CDK2 (CST, #2546;1:2000), CDC25A (CST, #3652;1 :1000), Cyclin E (CST, #4132; 1:2000), Bax (CST, #5023; 1:1000), Bcl-2 (CST, #2876; 1:1000), GBP1 (Abnova, #H00002633-PW1, 1:2000), β-actin (Novusbio, #NB600-501SS; 1:10000), Anti-mouse IgG HRP-binding antibody (CST, #7076, 1:5000), and Anti-rabbit IgG HRP-binding antibody (CST, #7074, 1:5000).
[0264] Whole YB-1 sandwich ELISA: Whole YB-1 protein levels were analyzed using the PathScan® Whole YB1 sandwich ELISA kit (Cell Signaling, #12543) according to the manufacturer's protocol.
[0265] Multidrug Resistance Assay: The effect of SU056 on multidrug resistance in various OC cells was assayed using a multidrug resistance assay kit (fluorometric MDR assay) (Sigma-Aldrich, #MAK161) according to the manufacturer's protocol.
[0266] CD44 ELISA: The effect of SU056 on CD44 expression in various OC cells was assayed using the Human CD44 ELISA Kit (colorimetric) (Novusbio, #NBP1-86819) according to the manufacturer's protocol.
[0267] Pull-down assay using biotinylated SU056: A protein pull-down assay was performed using biotinylated SU056. (1) Pull-down from cells: OVCAR8 cells were treated with 2.5 μM biotinylated SU056 for 1.5 hours. The treated cells were collected and lysed using M-PER® lysis solution (Thermo Scientific, #78503) supplemented with a Halt protease and phosphatase inhibitor cocktail (Thermo Scientific, #78440). 300 μg of protein was incubated overnight at 4°C on a shaker with magnetic conjugate streptavidin beads (CST, #5947). (2) Pull-down from cell lysates: OVCAR8 cells were collected and lysed using M-PER® lysis solution (Thermo Scientific, #78503) supplemented with a Halt protease and phosphatase inhibitor cocktail (Thermo Scientific, #78440). 1000 μg of protein was incubated overnight at 4°C on a shaker with 10 μM biotinylated SU056, and then incubated overnight at 4°C with magnetically conjugated streptavidin beads (CST, #5947). After both were pulled down, the biotin-streptavidin conjugate was pulled down and washed using a magnetic rack. After three washes, the beads were resuspended in 2× SDS sample buffer and then heated at 90–100°C for 5 minutes. The samples were separated and explored by GBP1 (Abnova, #H00002633-PW1, 1:2000) and YB-1 (CST, #8475; 1:2000) as in the immunoblotting described above. Samples of OVCAR8-derived protein lysates with and without biotinylated SU056 (2.5 μM) treatment (input), as well as samples from pull-downs using biotin alone and streptavidin beads alone, were separated as experimental controls.
[0268] Surface plasmon resonance (SPR): Experiments were performed at 25°C using a Biacore T200 (GE Healthcare) instrument. His-tagged (N-terminal) YB-1 protein (Novusbio, #NBP2-30101) was captured on an NTA chip (GE Healthcare) via the His tag and immobilized by amine coupling chemistry using N-hydroxysuccinimide (NHS) and N'-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) (GE Healthcare). All small molecule (SU093 and SU056) analysis experiments were performed in pH-adjusted PBS (10 mM phosphate buffer, 2.7 mM KCl, 0.137 NaCl) running buffer to give pH 7.4 when 5% DMSO was added. To investigate binding, six different concentrations (1–100 μM) of compounds, prepared from a 10 mM stock solution containing a final concentration of 5% DMSO, were injected onto different immobilized ligands at a flow rate of 30 μl / min for 75 or 120 seconds, with a regeneration time of 600 seconds. After each injection, the flow delivery system was washed with 50% DMSO. DMSO solvent-corrected curves were generated by injecting running buffer containing continuous concentrations of DMSO ranging from 4.5–5.8%. All data were corrected for nonspecific binding by subtracting the signals measured in control cells lacking the immobilized ligands.
[0269] Comprehensive proteome profiling: OVCAR8 cells were treated with vegetative medium or SU056 (2.5 μM) for 12 hours. Cells were washed and lysed (100 mM triethylammonium bicarbonate (TEAB, Thermo Fisher Scientific) with 1% sodium dodecyl sulfate (SDS)). Samples were prepared and labeled with TMT using the manufacturer's protocol (TMTsixplex® isobaric labeling reagent set, #90061, Thermo Fisher Scientific, Waltham, MA). Samples were analyzed using LC-MS / MS in three replicates, as previously described by our group (Going et al., 2018).
[0270] Calculation of Combination Index: Combination indexes (CIs) for paclitaxel and SU093 or SU056 were calculated using the Chou-Talalay method (Chou, 2010). CI values were calculated via CampuSyn software. CI<1, CI=1, and CI>1 indicate synergistic, additive, and antagonistic effects of the combination.
[0271] Paclitaxel Efflux Assay: OC cells were treated with paclitaxel (Molecular Probes, #P22310) conjugated with 5 nM Oregon Green® 488 for 1 hour. Cells were washed and incubated in phenol red-free DMEM medium supplemented with 10% FBS. After each time point (30 min, 60 min, 120 min, 180 min), the medium was collected and centrifuged to remove suspension cells. The fluorescence intensity of paclitaxel effluxed into the medium was read using a multimode plate reader with Ex 496 and Em 524.
[0272] Spheroid culture: OC cells were seeded at a density of 100 cells per well in ultra-low adhesion 24-well plates (Corning, #3473) in MEGM medium (Lonza, #CC-3150) supplemented with hEGF, insulin, hydrocortisone BPE, and 2-mercaptoethanol. Cells were treated with each compound and incubated for 6–8 days. The number of spheroids was counted under a 40x microscope. Five different fields from each well were imaged at 100x magnification.
[0273] In vivo xenograft models and drug efficacy studies: All animal studies were reviewed and approved by the Animal Care and Use Committee of Stanford University, CA, USA. Luciferase-tagged ID8 cells (2 × 10⁶ 6 ) or OVCAR8 cells (5 × 10 6The tumors were transplanted into the right flank of 6-7 week old female C57BL / 6 mice and NOD / SCID mice, respectively. 3 After proliferation to the specified diameter, each treatment was initiated. ID8 syngeneic mouse models were treated intraperitoneally (IP) daily for 42 days with a medium (30% PEG-300 in saline), 20 mg / kg SU093, and 20 mg / kg SU056. At the end of treatment, blood was collected from each mouse and analyzed for hepatotoxicity parameters, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALKP). OVCAR8 xenograft mouse models were treated for 4 weeks with a medium (30% PEG-300 in saline), 5 mg / kg paclitaxel (once weekly), 10 mg / kg SU056 (daily), and a combination of paclitaxel (5 mg / kg, once weekly) and SU056 (10 mg / kg, daily). Mice from both studies were euthanized, tumors and various organs were collected, fixed in neutral buffered formalin, and further processed for immunohistochemical analysis.
[0274] Immunohistochemistry: Fixed tumors and organs were paraffin-embedded. Each block was cut into 5 μm sections and fixed to slides coated with poly-L-lysine. The paraffin sections were deparaffinized and rehydrated. Antigen-retrieving sections were incubated with primary antibody, then with HRP-conjugated secondary antibody, and stained with Dab using the ImmPACT® DAB kit (Vectorlabs, CA). Counterstained sections were dehydrated and mounted using VectaMount® (Vectorlabs). Biotinylated equine anti-mouse IgG (Vectorlabs, CA) and equine anti-rabbit IgG (Vectorlabs, CA) were used as secondary antibodies. The following primary antibodies were used: YB-1 (Cell signaling, #8475; 1:100), anti-MDR1 (Cell signaling, #13978; 1:500), and Ki67 (Biolegend, #350502; 1:500).
[0275] Statistical Analysis: Each dataset was analyzed for statistical significance using GraphPad Prism 6 software. Each result is expressed as mean ± SD. The p-values are indicated using * as follows: * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001.
[0276] The presence of the expressed YBX1 protein in cancer cells as referred to herein can be identified by methods known in the art. Non-limiting examples include the YBX1 ELISA kit available from Antibodies-online Inc., Jones Blvd 321, Limerick, PA 19464 (catalog number ABIN6975583).
[0277] For immunohistochemical methods in human trials, YB1(D2B12) rabbit mAb #8475 (available online from Cell Signal Technology at https: / / www.cellsignal.com / products / primary-antibodies / yb1-d2b12-rabbit-mab / 8475?site-search-type=Products&N=4294956287&Ntt=ybx1&fromPage=plp).
[0278] significance Despite intensive chemotherapy regimens, delayed diagnosis and a high risk of recurrence, coupled with treatment resistance (TR) and high mortality, highlight the urgent need for new chemotherapy strategies to improve cancer treatment. Y-box binding protein 1 (YB1 or YBX1) is a multifunctional protein that binds to DNA and RNA and is associated with tumor progression and the emergence of TR. YB-1 plays a crucial role in the transcription, translation, and RNA stabilization of various oncogenic proteins. While the role of YB-1 is well-established in various cancers, no small molecule inhibitors have been available or reported to date. Hereafter, we report a novel azopodophyllotoxin (AzP) derivative, SU056, which inhibits disease progression via YB1 inhibition. This first-in-class YB-1 inhibitor potently inhibits the proliferation and resistance to apoptosis of ovarian cancer (OC) cells, causing cell arrest in the G1 phase. This treatment results in enrichment of proteins associated with the apoptotic and RNA degradation pathways and downregulates the spliceosome pathway. In vivo, SU056 independently inhibits ovarian cancer progression and, in synergy with paclitaxel, further reduces disease progression without hepatotoxicity. Furthermore, in vitro mechanistic studies showed delayed disease progression through inhibition of drug efflux and multidrug resistance 1 (MDR1), as well as significantly lower neurotoxicity compared to etoposide. These data suggest that YB-1 inhibitors may be an effective strategy for reducing OC progression, TR, and patient mortality.
[0279] Data availability The mass spectrometry proteomics data is registered in the PRIDE archive (http: / / www.ebi.ac.uk / pride / archive / ) via the PRIDE partner repository under the dataset identifier PXD022332.
[0280] References TIFF2023552368000016.tif165163TIFF2023552368000017.tif212165TIFF2023552368000018.tif22216 4TIFF2023552368000019.tif221165TIFF2023552368000020.tif212164TIFF2023552368000021.tif70161
[0281] Figure 1: (A) Read optimization of SU093 to obtain SU056. (B) IC of SU093 and SU056 against various ovarian cancer cells. 50 Values. Clonal viability of OC cells treated with SU093 or SU056. Ovarian cancer cells were seeded at 300-500 cells per well in a 12-well plate and allowed to adhere for 24 hours. Cells were treated with SU093 and SU056 and incubated for an additional 7 days. Each well was stained with crystal violet and colonies were counted under a 10x microscope. (C) Representative colony formation from each well. (D) Number of colonies formed after treatment with SU093 and SU056. (E) Percentage inhibition values of 48-hour treatment with 10 μM etoposide, SU093, and SU056 in nerve (SH-SY5Y, N27) cells and HEK293 cells. (F) Cell cycle distribution of OVCAR8, SKOV3, and ID8 cells stained with propidium iodide (PI). Effect of SU093 and SU056 on cell cycle distribution, showing G1 phase arrest after 12 hours of treatment. (G) Effects of SU093 and SU056 on apoptotic cell death analyzed by Annexin-FITC staining. Both compounds induce apoptotic cell death in ovarian cancer cells after 24 hours of treatment. (H) Cell migration assay. Imaging of cells 16 hours after passing through a Boyden chamber showed that treatment with SU093 and SU056 significantly reduced the cell migration characteristics of ovarian cancer cells. Data are shown as mean ± SD of three replicate samples. * P<0.05, significantly different from each control by one-way ANOVA followed by Dunnett's test.
[0282] Figure 2. SU093 and SU056 inhibit the growth of mouse ovarian ID-8 tumor xenografts in C57BL / 6 mice. ID-8 cells mixed with Matrigel in a 1:1 ratio were subcutaneously injected into mice, and the tumor grew to 100 mm. 3 Drug treatment was initiated when the following was reached. Either the medium (30% PEG300 in physiological saline) or 20 mg / kg of SU093 or SU056 was administered intraperitoneally (IP) to mice daily for 42 days. (A) Representative images of mice after 42 days of drug treatment showed tumor reduction compared to controls. (B) Tumor volume / mouse as a function of time. The data shown are mean ± SD from 5 mice in each group. * P<0.05, compared to each control. (C) Tumor weight / mouse at the end of the study. The data shown are mean ± SD from 5 mice in each group. * P<0.05, ** P<0.01, *** P<0.001, compared to each control. (D) Hepatotoxicity parameters at the end of 42 days, showing no significant difference between control and between SU093 and SU056. (E~F) Lung metastasis assay. (E) H&E staining of lungs (red arrows indicate metastasis from ID8 xenograft). Scale bar, 250 μm. (F) Number of lung metastatic nodules. The data shown are mean ± SD from 5 mice in each group. * P<0.05, ** P<0.01, *** P<0.001, compared to the respective control.
[0283] Figure 3: Target identification using cellular thermal shift assay (CETSA). Differential profiling of SU056 against the thermal proteome profile of OVCAR8 cells. OVCAR8 cells were treated with DMSO or SU056 (2.5 μM) for 1.5 hours. Cells were collected and 10 cells were extracted from each PCR tube. 6Individual cells were incubated at different temperatures (37°C, 41°C, 44°C, 47°C, 50°C, 53°C, 56°C, 59°C, 63°C, 67°C). Cells were lysed, an equal amount of soluble protein was labeled with TMT, and then LC-MS / MS analysis was performed. (A) Heat map display of the thermal stability of 804 soluble proteins in ovarian cancer cells treated with DMSO (left) and SU056 (right). (B) Density distribution of calculated protein Tm values in cells treated with SU056 (red) and media cells (blue). (C) Density distribution of Tm shift between SU056 treatment and media treatment. (D) Scatter plot of calculated Tm in SU056 treatment and media treatment. Proteins that met significance levels (p<0.01, RSQ>0.7) and identification criteria are highlighted in red. (E) Melting curves of the top 6 proteins identified with and without SU056 treatment (YB-1, TMSB10, SUMO-2, PSMB2, TMSB4X, and CALM3). (F) Melting temperature (T) of the top 6 proteins after SU056 treatment. m Changes in )
[0284] Figure 4: SU056 inhibits YB-1. (A) OVCAR8 cells were treated with SU056 (1 μM, 2.5 μM, and 5 μM) for 12 hours as described in the "Methods" section, and whole cell lysates were prepared. SDS-PAGE and Western blot analysis were performed for the top three targets identified by CETSA (YB-1, TMSB10, SUMO-2, and PSMB2). The membranes were stripped and re-searched with anti-β-actin antibodies to ensure equal protein loading. (B) Immunohistochemistry of tumor samples from ID8 tumor xenograft studies from the control and SU056 groups for YB-1 and MDR1 expression. Subset images are 20x magnification: scale bar, 50 μm. (C-E) Effects of SU056 on YB-1 and related proteins in different ovarian cancer cell lines. (C) Each OC cell line was treated with 2.5 μM SU056 for 12 hours as described in the "Methods" section, and YB-1 & CD44 expression and multidrug resistance activity were measured. For each cell line, the % inhibition was calculated and compared to the control. (D) 50% inhibitory concentration of YB-1 (IC) of SU056 for OC cell lines. 50 (E) YB-1 inhibition temporomandibular system study on the effect of SU056 on OC cell lines. Cells were treated with SU056 (1 μM, 2.5 μM, and 5 μM) for 3 hours, 6 hours, 12 hours, and 24 hours. YB-1 was assayed using the PathScan® whole YB1 sandwich ELISA kit.
[0285] Figure 5: SU056 physically interacts with YB-1. (A) Structure of biotinylated SU056. (B) Pull-down assay using biotinylated SU056. Pull-down assays were performed from OVCAR8 cells and OVCAR8 cell lysates as described in the "Methods" section. Both pull-down assays were repeated twice. (C-D) Representative sensograms for (C) SU093 and (D) SU056. His-tagged YB-1 protein was immobilized on an NTA chip as described in the "Methods" section, and different concentrations of SU093 and SU056 (1-100 μM) were tested for physical interaction. (E-G) The cellular effect of SU056 is dependent on YB-1 expression. Scrambled control (SC), YBX1 shRNA1, and YBX1 shRNA2 were stably expressed in OVCAR8 cells using lentiviral vectors. (E) Western blot analysis was performed to confirm YB-1 expression in transduced cells. (F) 500 cells (SC, shRNA1, shRNA2) were seeded per well in a 12-well plate and allowed to adhere for 24 hours. Transduced cells were treated with SU056 and incubated for a further 7 days. Each well was stained with crystal violet and colonies were counted under a 10x microscope. Representative colony formation from each well. (G) IC of SU056 in different transduced OVCAR8 cells expressing SC, YBX1 shRNA1, and YBX1 shRNA2. 50 value.
[0286] Figure 6: SU056 modulates YB-1-related proteins and pathways. (A) Cycloheximide chase assay (CHX) to measure the effect of SU056 on the stability of YB-1 protein. Data are shown as mean ± SD of three replicate samples. * P<0.05, significantly different from each control by one-way ANOVA and subsequent Dunnett test. (B) Whole cell lysates were prepared as described in the "Methods" section. SDS-PAGE and Western blot analysis were performed for YB-1, cell cycle markers, and apoptosis-related markers. Membranes were stripped and re-searched with anti-β-actin antibody to ensure equal protein loading. (C~F) GSEA was performed on proteomics results to determine the enrichment of the KEGG pathway upon SU056 treatment in the OVCAR8 cell line. (C) Enrichment plot of pathways modulated by SU056 treatment. (D~E) Enrichment of the apoptotic pathway and RNA degradation pathway was observed in proteins whose abundance increased upon treatment with SU056. (F) Enrichment of the spliceosome pathway was observed in proteins whose abundance decreased upon treatment with SU056.
[0287] Figure 7: SU056 treatment makes ovarian cancer cells sensitive to taxane treatment. (A) Sensitization effect of SU056 combined with paclitaxel treatment on the viability of OVCAR8 and SKOV3 cells. Cells treated with 0.1 μM, 0.5 μM, and 1 μM SU056, and then treated with 0.1 nM, 0.5 nM, and 1 nM paclitaxel for 48 hours, showed a synergistic cytotoxic effect. Combination index values for paclitaxel and SU056. (B) Alexa Fluor-488 tagged paclitaxel efflux assay showed that co-treatment with SU056 inhibited paclitaxel efflux. (C) Immunoblotting of YB-1 and MDR1. OVCAR8 cells were treated for 12 hours with either medium (C), paclitaxel (0.5 nM, P), SU056 (0.5 μM, 56), or paclitaxel + SU056 (P + 56) to prepare cell lysates. Proteins were separated on an SDS-PAGE gel and blotted for each antibody as described in the Methods section. The membrane was stripped and re-searched for loaded control actin. Spheroid formation assay. 500 cells were cultured in an ultra-low adhesion plate and treated with each drug and combinations thereof. Cells were incubated for 7 days to form spheroids. (D) Microscopic image of spheroids at 10x magnification. Scale bar, 250 μm. (E) Spheroid formation was quantified after 7 days of incubation. Data are shown as mean ± SD of 3 replicate samples. * P<0.05, ** P<0.01, *** P<0.001, significantly different compared to the respective controls by Dunnett's test following one-way ANOVA. (F~I) Combination study of SU056 and paclitaxel in an OVCAR8 xenograft model. NOD-SCID female mice were subcutaneously injected with OVCAR8 cells mixed with Matrigel in a 1:1 ratio. Tumors were 200 mm 3Drug treatment was initiated when the tumors proliferated. Mice were intraperitoneally (IP) injected with either a medium (30% PEG300 in saline) or 10 mg / kg SU056 (daily) and / or 5 mg / kg paclitaxel (once weekly) for 28 days (4 weeks). (F) Representative image of mice after 28 days of drug treatment showing tumor reduction compared to controls. (G) Tumor volume / mouse as a function of time. (H) Tumor weight / mouse at the end of the study. (I) Immunohistochemical staining. Tumor sections were stained with Ki67, and slides were scored for KI67 staining. The data shown are mean ± SD from 5 mice in each group. * P<0.05, ** P<0.01, *** P<0.001 (compared to their respective controls).
[0288] Figure 8: (A) Validation of CETSA results using Western blot analysis. Cell lysates from cells treated with controls exposed to temperatures of 37°C and 53°C, and cells treated with SU056, were analyzed for the expression of YB-1, TMSB10, and PSMB2. (B-C) SU056 treatment inhibits YB-1 expression in OVCAR8 cells. OVCAR8 cells stably expressing mCheery-tagged YB-1 were used for these assays. (B) Cells were imaged at 10x magnification using a confocal microscope for mCherry-YB1 after 3 hours of treatment with SU056 (2.5 & 5 μM). (C) 2500 cells were seeded in a 96-well plate (black wells, clear bottom) and treated with SU056 (1-5 μM) for 3 and 6 hours. Relative fluorescence intensity was measured using a multimode plate reader. Data were normalized by % live cells and presented as a percentage compared to untreated cells. The data shown are mean ± SD from 5 replicates for each group. * P < 0.05, compared to each control.
[0289] Figure 9: Sensitization effect of SU056 combined with paclitaxel treatment on the viability of OVCAR8 and SKOV3 cells. Cells treated with 0.1 μM, 0.5 μM, and 1 μM SU056, followed by 48 hours of treatment with 0.1 nM, 0.5 nM, and 1 nM paclitaxel, showed a synergistic cytotoxic effect.
[0290] Figure 10: Pharmacokinetics of SU056. Determination of SU056 plasma concentration as a function of time (minutes) after intraperitoneal administration of a 20 mg / kg dose of the drug (n=3). Plasma was collected at each time point after injection as described in the methods and analyzed using LC MS / MS.
[0291] Figure 11: (A) The growth inhibitory effect of SU056 was evaluated using the MTT assay. TNBC cell lines (MDA-MB-231, MDA-MB-468, SUM159, 4T1, E0771, and EMT6) were seeded in 96-well plates and treated the following day with 0.005–50 μM SU056 in a single medium (DMSO) or fresh medium. After 48 hours of treatment, cell viability was measured using the MTT assay. (B) 300–600 cells in total per well were seeded in 12-well plates and allowed to adhere for 24 hours. The following day, the cells were treated with SU056 and incubated for a further 7–10 days. Each well was stained with crystal violet, and colonies were counted under a 10x microscope. Representative colony formation from each well of cells. (C) Number of colonies formed after SU056 treatment. (D) Effect of SU056 on the cell cycle distribution of TNBC cells. MDA-MB-231, MDA-MB-468, and SUM159 cells were treated with either the medium or SU056 for 12 and 24 hours. At the end of treatment, cells were collected and analyzed using flow cytometry. SU056 treatment showed G2 / M phase arrest. SU056 induces intracellular phosphorylated histone H3 levels at 12 and 24 hours.
[0292] Figure 12. TNBC cells were treated for 12 and 24 hours, and whole cell lysates were prepared. SDS-PAGE and Western blot analysis were performed for translation-related molecules. β-actin was searched to ensure equal protein loading. SU056 treatment inhibited protein translation-related molecules in all TNBC cells, (A) MDA-MB-231, (B) MDA-MB-468, and (C) SUM159.
[0293] Figure 13. SU056 inhibits tumor xenografts in the TNBC model. MDA-MB-231 (2 × 10 6 cells), MDA-MB-468 (5 × 10 6 Cells, and patient-derived xenograft SUTI151-PDX (2 × 10⁻¹⁰⁻¹ 6 Cells were injected subcutaneously into mice, and the tumor grew to 100 mm. 3 Drug treatment was initiated when the following was reached. Either the medium (40% PEG in physiological saline) or SU056 (50 mg / kg) was administered to the mice orally via enteral nutrition. (A) Tumor volume as a function of time (MDA-MB-231). (B) Tumor weight at the end of the study (MDA-MB-231). (C) Body weight as a function of time (MDA-MB-231). (D) Tumor volume as a function of time (MDA-MB-468). (E) Tumor weight at the end of the study (MDA-MB-468). (F) Body weight as a function of time (MDA-MB-468). (G) Representative image of the tumor (MDA-MB-231) at the end of the study. (H) Representative image of the tumor (MDA-MB-468) at the end of the study. (I) Tumor volume as a function of time (SUTI151-PDX). (B) Tumor weight at the end of the study (SUTI151-PDX). (C) Weight as a function of time (SUTI151-PDX).
[0294] Figure 14. SU056 inhibits 4T1 tumor xenografts in BALB / c. Mice were subcutaneously injected with 4T1 cells, and drug treatment was initiated 3 days after transplantation. Mice were administered orally via enteral nutrition using either the medium (40% PEG in saline) or SU056 (50 mg / kg). (A) Tumor volume (4T1) as a function of time. (B) Tumor weight (4T1) at the end of the study. (C) Body weight (4T1) as a function of time. (D) Representative image of tumor (4T1) at the end of the study. Paclitaxel and SU056 combination in 4T1 xenograft model. (E) Tumor volume (4T1) as a function of time. (F) Tumor weight (4T1) at the end of the study. (G) Body weight (4T1) as a function of time.
[0295] Figure 15. SU056 treatment was well tolerated in mice and rats. Treatment with increasing concentrations of SU056 did not induce feeding behavior, as reflected in changes in body weight, in (A) mice and (B) rats. Treatment with different concentrations of SU056 did not cause death in (C) mice and (D) rats. Liver microsomes were used for metabolic profiling. (E) SU056 had an average half-life of 40 minutes.
[0296] Figure 16 illustrates the normalized expression levels of YBX1 against criteria for cancer cell lines: (a) Lung - IMR90, A549, MRC5, H1299, NHBE, NCIH460, and BEAS2; (b) Lymphocytes - JURKAT, MT4, BJAB, HEL cells, HL60, and RAJI; (c) Breast / Mammary gland - MCF7, MCF10, MDAMB231, SKBR3, MDAMB468, and MDAMB453; (d) Fibroblasts - BJ, KB, HT1080, NHDF, and TIG; (e) Prostate - LNCAP, PC3 、DU145 and C42; (f) Others - NALM6, DAOY, JEG3, and BEWO; (g) Kidney - 293T, HEK293, 293F, and FLPIN TREX 293; (h) Blood - THP1, PLB985, CEM, and HELAT4; (i) Ovaries - SKOV3, 2008, and OVCAR3; (j) Skin - HNSCC and A431; (k) Sarcoma - LHCNM2 and U2OS; (l) Lymphatic system - REH and RPMI8226; (m) Colon - HCT116 and HT29; (n) Cervical - HELA and HELA S3; (o) Brain - SHSY5Y and SKNMC; (p) Bone - K562 and U2OS; (q) Uterus - BEWO; (r) Pancreas - PANC1; (s) Neuroblastoma - IMR32; (t) Macrophage U937; (u) Liver - HEPG2; (v) Keratinocyte - HACAT; (w) Glial gland - H4; (x) Connective tissue - G401; (y) Bone marrow - KG1 cells; and (a) Bladder - T24. This information is provided online by the Ma'ayan Lab Data Coordination and Integration Center at the Mount Sinai Center for Bioinformatics and is accessible at https: / / maayanlab.cloud / archs4 / gene / YBX1#correlation.
[0297] Figure 17: Assay of SU056 in an NCI-60 cell line panel. SU056 was assayed against an NCI-60 cell line panel at five doses (100-0.01 μM) for 48 hours, and IC50 was obtained. 50 The values are provided in the table below. Growth inhibition was measured and displayed as a heatmap ranging from no inhibition (black) to growth inhibition (white), as shown in Figure 17. NCI60 - IC50 values TIFF2023552368000022.tif122128TIFF2023552368000023.tif19660
[0298] In Figures 18, 19, and 20, TNBC cells were treated for 12 and 24 hours, and whole cell lysates were prepared. SDS-PAGE and Western blot analysis were performed for translation-related molecules. β-actin was searched to ensure equal protein loading. SU056 treatment inhibited translation initiation factors in TNBC cells.
[0299] STAR Method List of major resources TIFF2023552368000024.tif187166TIFF2023552368000025.tif166166
[0300] Human YB-1 protein (His-tagged) (Novus Biological catalog number NBP2-30101) is a recombinant protein with an N-terminal His tag, corresponding to amino acids 1-324 of human YB1. Origin: Escherichia coli (E. coli). Gene: YBX1. Amino acid sequence: TIFF2023552368000026.tif51162
Claims
1. A pharma- ceutically effective amount of a compound of formula (I): or a pharma- ceutical acceptable salt, co-crystal, ester, solvate, hydrate, isomer, tautomer, isotope, polymorph, or prodrug thereof, for inhibiting YB1 protein activity in a subject suffering from a cancer expressing YB1 protein, In the formula, X is R 1 , R 2 , R 3 , R 4 , and R 5 is H, F, C 1 -C 4 Fluoroalkyl, SF 5 , Cl, Br, I, OH, C 1 -C 4 Alkyl, C 1 -C 4 Alkoxy, CN, NO 2 and OH; n is an integer independently selected at each occurrence from the group of 2, 1, 3, 4, 5, and 6; R 6 , H, C 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl, -(CH 2 ) n -C 3 -C 6 Cycloalkyl, 3- to 6-membered heterocycle, -(CH 2 ) n -3 to 6 membered heterocycles, phenyl, and -(CH 2 ) n -phenyl; C 1 -C 6 The alkyl groups are F, Cl, Br, I, OH, CN, and NO. 2 and OH; 3 -C 6 Cycloalkyl, -(CH 2 ) n -C 3 -C 6 Cycloalkyl, 3- to 6-membered heterocycle, -(CH 2 ) n -3 to 6 membered heterocycles, phenyl, and -(CH 2 ) n -Phenyl group is C 1 -C 3 Alkyl, C 1 -C 3 Alkoxy, F, Cl, Br, I, OH, CN, NO 2 and OH; However, R 1 , R 2 , R 3 , R 4 , and R 5 At least one of the following is F, C 1 -C 4 Fluoroalkyl, and SF 5 selected from the group Pharmaceutical compositions.
2. The pharmaceutical composition of claim 1, wherein the compound of formula (I) is 9-(3-fluorophenyl)-5-(2-hydroxyethyl)-6,9-dihydro-[1,3]dioxolo[4,5-g]furo[3,4-b]quinolin-8(5H)-one (SU056) or a pharma- ceutically acceptable salt, pharma- ceutically acceptable cocrystal, ester, solvate, hydrate, isomer, tautomer, isotope, polymorph, or prodrug thereof.
3. The compound of formula (I) is a compound of formula (Ia): or a pharma- ceutically acceptable salt, co-crystal, ester, solvate, hydrate, isomer, tautomer, isotope, polymorph, or prodrug thereof; In the formula, n, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 is as defined in claim 1, 2. The pharmaceutical composition of claim 1.
4. The compound of formula (I) is a compound of formula (Ib): or a pharma- ceutically acceptable salt, co-crystal, ester, solvate, hydrate, isomer, tautomer, isotope, polymorph, or prodrug thereof; In the formula, n, R 2 , R 3 , R 4 , R 5 , and R 6 is as defined in claim 1, 2. The pharmaceutical composition of claim 1.
5. The compound of formula (I) is a compound of formula (Ic): or a pharma- ceutically acceptable salt, co-crystal, ester, solvate, hydrate, isomer, tautomer, isotope, polymorph, or prodrug thereof; In the formula, n, R 1 , R 3 , R 4 , R 5 , and R 6 is as defined in claim 1, 2. The pharmaceutical composition of claim 1.
6. The compound of formula (I) is a compound of formula (Id): or a pharma- ceutically acceptable salt, co-crystal, ester, solvate, hydrate, isomer, tautomer, isotope, polymorph, or prodrug thereof; In the formula, n, R 1 , R 2 , R 4 , R 5 , and R 6 is as defined in claim 1, 2. The pharmaceutical composition of claim 1.
7. The compound of formula (I) is a compound of formula (II): or a pharma- ceutically acceptable salt, co-crystal, ester, solvate, hydrate, isomer, tautomer, isotope, polymorph, or prodrug thereof; In the formula, R 1 , R 2 , R 3 , R 4 , and R 5 is H, F, C 1 -C 4 Fluoroalkyl, SF 5 , Cl, Br, I, OH, C 1 -C 4 Alkyl, C 1 -C 4 Alkoxy, CN, NO 2 each independently selected from the group: n is an integer independently selected at each occurrence from the group of 1, 2, 3, 4, 5, and 6; R 6 , H, C 1 -C 6 Alkyl, C 3 -C 6 Cycloalkyl, -(CH 2 ) n -C 3 -C 6 Cycloalkyl, 3- to 6-membered heterocycle, -(CH 2 ) n -3 to 6 membered heterocycles, phenyl, and -(CH 2 ) n -phenyl; C 1 -C 6 The alkyl groups are F, Cl, Br, I, OH, CN, and NO. 2 and OH; 3 -C 6 Cycloalkyl, -(CH 2 ) n -C 3 -C 6 Cycloalkyl, 3- to 6-membered heterocycle, -(CH 2 ) n -3 to 6 membered heterocycles, phenyl, and -(CH 2 ) n -Phenyl group is C 1 -C 3 Alkyl, C 1 -C 3 Alkoxy, F, Cl, Br, I, OH, CN, NO 2 and OH; However, R 1 , R 2 , R 3 , R 4 , and R 5 At least one of the following is F, C 1 -C 4 Fluoroalkyl, and SF 5 selected from the group However, R 2 is F or CF 3 If so, then R 1 , R 3 , R 4 , and R 5 At least one of is not H, 2. The pharmaceutical composition of claim 1.
8. The compound of formula (I) is a compound of formula (III): or a pharma- ceutically acceptable salt, co-crystal, ester, solvate, hydrate, isomer, tautomer, isotope, polymorph, or prodrug thereof; wherein n is an integer independently selected at each occurrence from the group of 1, 2, 3, 4, 5, and 6; R 1 , R 2 , R 3 , R 4 , and R 5 is H, F, C 1 -C 4 Fluoroalkyl, SF 5 , Cl, Br, I, OH, C 1 -C 4 Alkyl, C 1 -C 4 Alkoxy, CN, NO 2 each independently selected from the group: However, R 1 , R 2 , R 3 , R 4 , and R 5 At least one of the following is F, C 1 -C 4 Fluoroalkyl, and SF 5 selected from the group However, R 2 is F or CF 3 If so, then R 1 , R 3 , R 4 , and R 5 At least one of is not H, 2. The pharmaceutical composition of claim 1.
9. R 1 But, F, C 1 -C 4 Fluoroalkyl, and SF 5 R 2 , R 3 , R 4 , and R 5 But H, F, C 1 -C 4 Fluoroalkyl, SF 5 , Cl, Br, I, OH, C 1 -C 4 Alkyl, C 1 -C 4 Alkoxy, CN, NO 2 and OH, 9. The pharmaceutical composition of claim 8.
10. R 3 But, F, C 1 -C 4 Fluoroalkyl, and SF 5 R 1 , R 2 , R 4 , and R 5 But H, F, C 1 -C 4 Fluoroalkyl, SF 5 , Cl, Br, I, OH, C 1 -C 4 Alkyl, C 1 -C 4 Alkoxy, CN, NO 2 and OH, 10. The pharmaceutical composition of any one of claims 8 and 9.
11. R 1 , R 2 , R 3 , R 4 , and R 5 But H, F, C 1 -C 4 Fluoroalkyl, SF 5 , Cl, Br, I, OH, C 1 -C 4 Alkyl, C 1 -C 4 Alkoxy, CN, NO 2 each independently selected from the group: However, R 1 , R 2 , R 3 , R 4 , and R 5 At least two of the following are F, C 1 -C 4 Fluoroalkyl, and SF 5 selected from the group 11. The pharmaceutical composition of any one of claims 8, 9 and 10.
12. R 1 , R 2 , R 3 , R 4 , and R 5 But H, F, C 1 -C 3 Fluoroalkyl, SF 5 , Cl, Br, I, OH, C 1 -C 4 Alkyl, C 1 -C 4 Alkoxy, CN, NO 2 each independently selected from the group: However, R 1 , R 2 , R 3 , R 4 , and R 5 At least two of the following are F, C 1 -C 3 fluoroalkyl, 12. The pharmaceutical composition of any one of claims 8, 9, 10, and 11.
13. R 1 , R 2 , R 3 , R 4 , and R 5 But H, F, CF 3 ,SCIENCE FICTION 5 , Cl, Br, I, OH, C 1 -C 4 Alkyl, C 1 -C 4 Alkoxy, CN, NO 2 each independently selected from the group: However, R 1 , R 2 , R 3 , R 4 , and R 5 At least two of the following are F and CF 3 selected from the group 13. The pharmaceutical composition of any one of claims 8, 9, 10, 11, and 12.
14. R 1 , R 2 , R 3 , R 4 , and R 5 But H, F, CF 3 ,SCIENCE FICTION 5 , Cl, Br, I, OH, C 1 -C 4 Alkyl, C 1 -C 4 Alkoxy, CN, NO 2 each independently selected from the group: However, R 1 , R 2 , R 3 , R 4 , and R 5 at least two of are F; 14. The pharmaceutical composition of any one of claims 8, 9, 10, 11, 12, and 13.
15. n is an integer independently selected at each occurrence from the group of 1, 2, 3, 4, and 5; 15. The pharmaceutical composition of any one of claims 1 and 3 to 14.
16. n is an integer independently selected at each occurrence from the group of 1, 2, 3, and 4; 15. The pharmaceutical composition of any one of claims 1 and 3 to 14.
17. n is an integer independently selected at each occurrence from the group of 1, 2, and 3; 15. The pharmaceutical composition of any one of claims 1 and 3 to 14.
18. n is an integer independently selected at each occurrence from the group of 2 and 3; 15. The pharmaceutical composition of any one of claims 1 and 3 to 14.
19. n is 1, 15. The pharmaceutical composition of any one of claims 1 and 3 to 14.
20. n is 2, 15. The pharmaceutical composition of any one of claims 1 and 3 to 14.
21. n is 3, 15. The pharmaceutical composition of any one of claims 1 and 3 to 14.
22. n is 4, 15. The pharmaceutical composition of any one of claims 1 and 3 to 14.
23. n is 5, 15. The pharmaceutical composition of any one of claims 1 and 3 to 14.
24. n is 6, 15. The pharmaceutical composition of any one of claims 1 and 3 to 14.
25. R 6 is H, 25. The pharmaceutical composition of any one of claims 1 and 3 to 24.
26. R 6 But, C 1 -C 3 Alkyl, C 1 -C 3 Alkoxy, F, Cl, Br, I, OH, CN, NO 2 C substituted with 0, 1, 2, 3, or 4 substituents selected from the group consisting of 1 -C 6 is alkyl, 26. The pharmaceutical composition of any one of claims 1 and 3 to 25.
27. R 6 C 3 -C 6 Cycloalkyl, C 3 -C 6 Cycloalkyl is C 1 -C 3 Alkyl, C 1 -C 3 Alkoxy, F, Cl, Br, I, OH, CN, NO 2 and OH; 27. The pharmaceutical composition of any one of claims 1 and 3 to 26.
28. R 6 Ga-(CH 2 ) n -C 3 -C 6 Cycloalkyl, C 3 -C 6 The cycloalkyl ring is C 1 -C 3 Alkyl, C 1 -C 3 Alkoxy, F, Cl, Br, I, OH, CN, NO 2 and OH; 27. The pharmaceutical composition of any one of claims 1 and 3 to 26.
29. R 6 is a 3- to 6-membered heterocyclic ring, 1 -C 3 Alkyl, C 1 -C 3 Alkoxy, F, Cl, Br, I, OH, CN, NO 2 and OH; 27. The pharmaceutical composition of any one of claims 1 and 3 to 26.
30. R 6 Ga-(CH 2 ) n -3-6 membered heterocycle, the heterocycle being 1 -C 3 Alkyl, C 1 -C 3 Alkoxy, F, Cl, Br, I, OH, CN, NO 2 and OH; 27. The pharmaceutical composition of any one of claims 1 and 3 to 26.
31. R 6 is phenyl, and the phenyl ring is C 1 -C 3 Alkyl, C 1 -C 3 Alkoxy, F, Cl, Br, I, OH, CN, NO 2 and OH; 27. The pharmaceutical composition of any one of claims 1 and 3 to 26.
32. R 6 Ga-(CH 2 ) n -phenyl, the phenyl ring being C 1 -C 3 Alkyl, C 1 -C 3 Alkoxy, F, Cl, Br, I, OH, CN, NO 2 and OH; 27. The pharmaceutical composition of any one of claims 1 and 3 to 26.
33. R 1 , R 2 , R 3 , R 4 , and R 5 If two of the are present, F, C 1 -C 4 Fluoroalkyl, and SF 5 33. The pharmaceutical composition of any one of claims 1 and 3 to 32, selected from the group consisting of:
34. R 1 , R 2 , R 3 , R 4 , and R 5 If two of the are present, F, C 1 -C 3 34. The pharmaceutical composition of any one of claims 1 and 3 to 33, wherein said compound is selected from the group of fluoroalkyl.
35. R 1 , R 2 , R 3 , R 4 , and R 5 Two of the following, if present, are F and CF 3 35. The pharmaceutical composition of any one of claims 1 and 3 to 34, selected from the group consisting of:
36. R 1 , R 2 , R 3 , R 4 , and R 5 Three of the following, if present, are F and CF 3 33. The pharmaceutical composition of any one of claims 1 and 3 to 32, selected from the group consisting of:
37. R 1 , R 2 , R 3 , R 4 , and R 5 Four of the following, if present, are F and CF 3 33. The pharmaceutical composition of any one of claims 1 and 3 to 32, selected from the group consisting of:
38. R 1 , R 2 , R 3 , R 4 , and R 5 The pharmaceutical composition of any one of claims 1 and 3-37, wherein two of, if present, are F.
39. R 1 , R 2 , R 3 , R 4 , and R 5 The pharmaceutical composition of any one of claims 1 and 3-37, wherein three of, if present, are F.
40. 40. A pharmaceutical composition comprising a pharma- ceutically effective amount of a compound of formula (I) according to any one of claims 1 to 39 or a pharma- ceutically acceptable salt, co-crystal, ester, solvate, hydrate, isomer, tautomer, isotope, polymorph, or prodrug thereof, and a pharma- ceutically acceptable carrier or excipient.
41. Use of a compound of formula (I) according to any one of claims 1 to 39 or a pharma- ceutically acceptable salt, co-crystal, ester, solvate, hydrate, isomer, tautomer, isotope, polymorph, or prodrug thereof in the preparation of a medicament for the treatment of a cancer expressing the YB1 protein.
42. A pharmaceutical composition for sensitizing cancer cells expressing YB1 protein in a subject to treatment with an anticancer drug, comprising a pharma- ceutically effective amount of a compound of formula (I) according to any one of claims 1 to 39 or a pharma- ceutically acceptable salt, pharma- ceutically acceptable cocrystal, ester, solvate, hydrate, isomer, tautomer, isotope, polymorph, or prodrug thereof.
43. A pharmaceutical composition for sensitizing cancer cells expressing YB1 protein in a subject to treatment with radiation, comprising a pharma- ceutically effective amount of a compound of formula (I) described in any one of claims 1 to 39 or a pharma- ceutically acceptable salt, pharma- ceutically acceptable cocrystal, ester, solvate, hydrate, isomer, tautomer, isotope, polymorph, or prodrug thereof.
44. The pharmaceutical composition according to any one of claims 1 to 43, wherein the cancer expressing YB1 protein is selected from the group consisting of gynecological cancer (including ovarian, endometrial, fallopian tube and cervical cancer), breast cancer, lung cancer, prostate cancer, colorectal cancer, bladder cancer, melanoma, liver cancer, multiple myeloma, soft tissue sarcoma, osteosarcoma, Ewing's sarcoma, glioblastoma, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, lymphoma, kidney cancer, renal cell carcinoma, osteosarcoma, pancreatic cancer, head and neck cancer, nasopharyngeal cancer and gastric cancer.
